RENOVARE ENVIRONMENTAL, INC. - Quarter Report: 2019 March (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended: March 31, 2019
or
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ________________ to ________________
Commission file number 001-36843
BIOHITECH GLOBAL, INC.
(Exact name of registrant as specified in its charter)
Delaware | 46-2336496 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
80 Red Schoolhouse Road, Suite 101 Chestnut Ridge, New York |
10977 | |
(Address of principal executive offices) | (Zip Code) |
(845) 262-1081
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨ | Accelerated filer ¨ |
Non-accelerated filer x | Smaller reporting company x |
Emerging growth company ¨ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, $0.0001 par value per share | BHTG | NASDAQ Capital Market |
The number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.
Class | Outstanding as of May 7, 2019 | |
Common Stock, $0.0001 par value per share | 14,907,956 shares |
BioHiTech Global, Inc. and Subsidiaries
TABLE OF CONTENTS
PART I - | FINANCIAL INFORMATION |
Item 1. | Financial Statements |
BioHiTech Global, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
Three Months Ended March 31, | ||||||||
2019 | 2018 | |||||||
Revenue | ||||||||
Rental, service and maintenance | $ | 487,701 | $ | 440,493 | ||||
Equipment sales | - | 65,850 | ||||||
Management advisory and other fees (related party) | 250,000 | 139,383 | ||||||
Total revenue | 737,701 | 645,726 | ||||||
Operating expenses | ||||||||
Rental, service and maintenance | 304,705 | 335,962 | ||||||
Equipment sales | - | 26,547 | ||||||
Selling, general and administrative | 2,326,362 | 1,579,990 | ||||||
Depreciation and amortization | 27,937 | 30,716 | ||||||
Total operating expenses | 2,659,004 | 1,973,215 | ||||||
Loss from operations | (1,921,303 | ) | (1,327,489 | ) | ||||
Other expenses | ||||||||
Equity loss in affiliate | - | 45,413 | ||||||
Interest expense, net | 339,864 | 554,276 | ||||||
Interest expense incurred in warrant valuation and conversions | - | 3,293,613 | ||||||
Total other expenses, net | 339,864 | 3,893,302 | ||||||
Net loss | (2,261,167 | ) | (5,220,791 | ) | ||||
Net loss attributable to non-controlling interests | (311,701 | ) | - | |||||
Net loss attributable to Parent | (1,949,466 | ) | (5,220,791 | ) | ||||
Foreign currency translation adjustment | 1,253 | (33,442 | ) | |||||
Comprehensive loss | $ | (1,948,213 | ) | $ | (5,254,233 | ) | ||
Net loss attributable to Parent | $ | (1,949,466 | ) | $ | (5,220,791 | ) | ||
Less – preferred stock dividends | (127,919 | ) | (91,039 | ) | ||||
Net loss – common shareholders | (2,077,385 | ) | (5,311,830 | ) | ||||
Net loss per common share - basic and diluted | $ | (0.14 | ) | $ | (0.49 | ) | ||
Weighted average number of common shares outstanding - basic and diluted | 14,816,734 | 10,940,183 |
See accompanying notes to unaudited interim consolidated financial statements.
1 |
BioHiTech Global, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
March 31, | December 31, | |||||||
2019 | 2018 | |||||||
(Unaudited) | ||||||||
Assets | ||||||||
Current Assets | ||||||||
Cash | $ | 1,374,564 | $ | 2,410,709 | ||||
Restricted cash | 2,137,456 | 4,195,148 | ||||||
Accounts receivable, net | 342,276 | 403,298 | ||||||
Inventory | 430,417 | 499,848 | ||||||
Prepaid expenses and other current assets | 126,585 | 66,425 | ||||||
Total Current Assets | 4,411,298 | 7,575,428 | ||||||
Restricted cash | 2,532,933 | 2,520,523 | ||||||
Equipment on operating leases, net | 1,655,963 | 1,748,887 | ||||||
Equipment, fixtures and vehicles, net | 43,544 | 49,028 | ||||||
HEBioT facility under construction | 35,899,019 | 33,104,007 | ||||||
Operating lease right of use assets | 1,021,190 | - | ||||||
Intangible assets, net | 61,383 | 83,933 | ||||||
Investment in unconsolidated affiliates | 1,687,383 | 1,687,383 | ||||||
MBT facility development and license costs | 8,076,353 | 8,475,408 | ||||||
Goodwill | 58,000 | 58,000 | ||||||
Other assets | 13,500 | 13,500 | ||||||
Total Assets | $ | 55,460,566 | $ | 55,316,097 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current Liabilities: | ||||||||
Line of credit, net of financing costs of $29,168 and $30,670 as of March 31, 2019 and December 31, 2018, respectively | $ | 1,470,832 | $ | 1,469,330 | ||||
Advance from related party | 150,000 | - | ||||||
Accounts payable | 4,391,816 | 1,310,998 | ||||||
Accrued interest payable | 501,871 | 959,927 | ||||||
Accrued expenses and liabilities | 878,356 | 3,354,124 | ||||||
Deferred revenue | 112,292 | 98,596 | ||||||
Customer deposits | 12,034 | 7,683 | ||||||
Note Payable | 100,000 | - | ||||||
Long-term debt, current portion | 8,362 | 9,165 | ||||||
Total Current Liabilities | 7,625,563 | 7,209,823 | ||||||
Note payable | - | 100,000 | ||||||
Junior note due to related party, net of discounts of $112,928 and $118,266 as of March 31, 2019 and December 31, 2018, respectively | 931,548 | 926,211 | ||||||
Accrued interest (related party) | 1,381,914 | 1,305,251 | ||||||
WV EDA Senior Secured Bonds payable, net of financing costs of $1,930,163 and $1,914,098 as of March 31, 2019 and December 31, 2018, respectively | 31,069,837 | 31,085,902 | ||||||
Senior Secured Note, net of financing costs of $148,665 and $160,017 and discounts of $924,951 and $988,678, as of March 31, 2019 and December 31, 2018, respectively | 3,926,384 | 3,851,305 | ||||||
Non-current lease liabilities | 919,713 | - | ||||||
Long-term debt, net of current portion | 11,345 | 12,806 | ||||||
Total Liabilities | 45,866,304 | 44,491,298 | ||||||
Series A redeemable convertible preferred stock, 333,401 shares designated and issued, and 163,312 outstanding as of March 31, 2019 and December 31, 2018 | 816,553 | 816,553 | ||||||
Commitments and Contingencies | - | - | ||||||
Stockholders' Equity | ||||||||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 3,179,120 and 3,159,120 designated as of March 31, 2019 and December 31, 2018, 1,911,253 issued and 1,162,833 outstanding as of March 31, 2019 and 1,903,753 issued and 1,155,333 outstanding as of December 31, 2018: | ||||||||
Series B Convertible preferred stock, 1,111,200 shares designated: 428,333 shares issued, no shares outstanding as of March 31, 2019 and December 31, 2018 | - | - | ||||||
Series C Convertible preferred stock, 1,000,000 shares designated, 427,500 shares issued and outstanding as of March 31, 2019 and December 31, 2018 | 3,050,142 | 3,050,142 | ||||||
Series D Convertible preferred stock, 20,000 shares designated: 7,500 shares issued and outstanding as of March 31, 2019 and no shares issued and outstanding as of December 31, 2018 | 750,000 | - | ||||||
Series E Convertible preferred stock, 714,519 shares designated: 714,519 shares issued, and 564,519 outstanding as of March 31, 2019 and December 31, 2018 | 1,490,330 | 1,490,330 | ||||||
Common stock, $0.0001 par value, 50,000,000 shares authorized, 14,822,956 and 14,802,956 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively | 1,482 | 1,480 | ||||||
Additional paid in capital | 43,750,710 | 43,452,963 | ||||||
Accumulated deficit | (46,562,223 | ) | (44,594,385 | ) | ||||
Accumulated other comprehensive income | 6,274 | 5,021 | ||||||
Stockholders’ equity attributable to Parent | 2,486,715 | 3,405,551 | ||||||
Stockholders’ equity attributable to non-controlling interests | 6,290,994 | 6,602,695 | ||||||
Total Stockholders’ Equity | 8,777,709 | 10,008,246 | ||||||
Total Liabilities and Stockholders’ Equity | $ | 55,460,566 | $ | 55,316,097 |
See accompanying notes to unaudited interim consolidated financial statements.
2 |
BioHiTech Global, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Unaudited)
Three Months Ended March 31, |
||||||||
2019 | 2018 | |||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | (2,261,167 | ) | $ | (5,220,791 | ) | ||
Adjustments to reconcile net loss to net cash used in operations: | ||||||||
Depreciation and amortization | 129,435 | 115,752 | ||||||
Amortization of operating lease right of use assets | 24,565 | - | ||||||
Provision for bad debts | 15,000 | 11,734 | ||||||
Share based employee compensation | 297,749 | 77,640 | ||||||
Interest resulting from amortization of financing costs and discounts | 109,793 | 287,512 | ||||||
Equity loss in affiliate | - | 45,413 | ||||||
Interest resulting from warrants valued upon conversion of host debt instruments | - | 3,293,613 | ||||||
Loss resulting from abandonment of MBT site | 346,654 | - | ||||||
Changes in operating assets and liabilities | 125,322 | (611,400 | ) | |||||
Net cash used in operating activities | (1,212,649 | ) | (2,000,527 | ) | ||||
Cash flow from investing activities: | ||||||||
Purchases of construction in-progress, equipment, fixtures and vehicles | (2,794,824 | ) | (1,602 | ) | ||||
MBT facility development costs incurredv | (13,600 | ) | (92,764 | ) | ||||
MBT facility development costs refunded | 66,000 | - | ||||||
Net cash used in investing activities | (2,742,424 | ) | (94,366 | ) | ||||
Cash flows from financing activities: | ||||||||
Proceeds from issuance of senior secured credit facility and common stock | - | 5,000,000 | ||||||
Repayment of line of credit facility | - | (2,463,736 | ) | |||||
Proceeds from new line of credit facility | - | 1,000,000 | ||||||
Proceeds from the sale of Series D convertible preferred stock units | 750,000 | - | ||||||
Deferred financing costs incurred | (43,941 | ) | (237,187 | ) | ||||
Repayments of long-term debt | (2,264 | ) | (2,192 | ) | ||||
Proceeds from the subscription of Series B convertible preferred stock and warrants | - | 1,125,000 | ||||||
Related party advance | 150,000 | - | ||||||
Net cash provided by financing activities | 853,795 | 4,421,885 | ||||||
Effect of exchange rate on cash | 19,851 | (4,657 | ) | |||||
Net change in cash (restricted and unrestricted) | (3,081,427 | ) | 2,322,335 | |||||
Cash - beginning of period (restricted and unrestricted) | 9,126,380 | 901,112 | ||||||
Cash - end of period (restricted and unrestricted) | $ | 6,044,953 | $ | 3,223,447 |
Note 21 includes supplemental cash flow information, non-cash investing and financing activities and changes in operating assets and liabilities.
See accompanying notes to unaudited interim consolidated financial statements.
3 |
BioHiTech Global, Inc. and Subsidiaries
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) (Unaudited)
Statement of Stockholders’ Equity Attributable to Parent for the Three Months Ended March 31, 2019: | ||||||||||||||||||||||||||||||||
Preferred Stock | Common Stock | Additional Paid in |
Accumulated Comprehensive |
Accumulated | ||||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Capital | Other Loss | Deficit | Total | |||||||||||||||||||||||||
Balance at January 1, 2019 | 992,019 | $ | 4,540,472 | 14,802,956 | $ | 1,480 | $ | 43,452,963 | $ | 5,021 | $ | (44,594,385 | ) | $ | 3,405,551 | |||||||||||||||||
Series D preferred stock | 7,500 | 750,000 | 750,000 | |||||||||||||||||||||||||||||
Share-based employee and director compensation | 297,749 | 297,749 | ||||||||||||||||||||||||||||||
Issuance of restricted stock | 20,000 | 2 | (2 | ) | - | |||||||||||||||||||||||||||
Preferred stock dividends | (18,372 | ) | (18,372 | ) | ||||||||||||||||||||||||||||
Net loss | (1,949,466 | ) | (1,949,466 | ) | ||||||||||||||||||||||||||||
Foreign currency translation adjustment | 1,253 | 1,253 | ||||||||||||||||||||||||||||||
Balance at March 31, 2019 | 999,519 | $ | 5,290,472 | 14,822,956 | $ | 1,482 | $ | 43,750,710 | $ | 6,274 | $ | (46,562,223 | ) | $ | 2,486,715 | |||||||||||||||||
Statement of Stockholders’ Equity Attributable to Non-Controlling Interests in Consolidated Subsidiaries for the Three Months Ended March 31, 2019: | ||||||||||||||||||||||||||||||||
Non-Controlling | Accumulated | |||||||||||||||||||||||||||||||
Equity Interest | Deficit | Total | ||||||||||||||||||||||||||||||
Balance at January 1, 2019 | $ | 6,679,585 | $ | (76,890 | ) | $ | 6,602,695 | |||||||||||||||||||||||||
Net loss | (311,701 | ) | (311,701 | ) | ||||||||||||||||||||||||||||
Balance at March 31, 2019 | $ | 6,679,585 | $ | (388,591 | ) | $ | 6,290,994 |
Statement of Stockholders’ Equity Attributable to Parent for the Three Months Ended March 31, 2018: | ||||||||||||||||||||||||||||||||
Preferred Stock | Common Stock | Additional Paid in | Accumulated Comprehensive | Accumulated | ||||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Capital | Other Loss | Deficit | Total | |||||||||||||||||||||||||
Balance at January 1, 2018 | 160,000 | $ | 699,332 | 9,598,208 | $ | 960 | $ | 17,752,990 | $ | (38,590 | ) | $ | (29,431,416 | ) | $ | (11,016,724 | ) | |||||||||||||||
Issuance of Series B preferred stock | 268,333 | 1,068,039 | 273,626 | 1,341,665 | ||||||||||||||||||||||||||||
Issuance of Series C preferred stock | 427,500 | 3,050,142 | 1,360,681 | 4,410,823 | ||||||||||||||||||||||||||||
Common stock issued for acquisition of Gold Medal Group | 500,000 | 50 | 2,249,950 | 2,250,000 | ||||||||||||||||||||||||||||
Share-based employee and director compensation | 77,640 | 77,640 | ||||||||||||||||||||||||||||||
Share-based professional services compensation | 30,000 | 3 | (3 | ) | - | |||||||||||||||||||||||||||
Conversion of debt into common stock | 1,349,577 | 135 | 3,715,239 | 3,715,374 | ||||||||||||||||||||||||||||
Interest on converted debt in common stock | 104,889 | 10 | 523,778 | 523,788 | ||||||||||||||||||||||||||||
Common stock issued in connection with debt financings | 320,000 | 32 | 1,212,089 | 1,212,121 | ||||||||||||||||||||||||||||
Warrants valued in connection with debt conversions and amendments | 23,243 | 2 | 3,293,611 | 3,293,613 | ||||||||||||||||||||||||||||
Foreign currency translation adjustment | (33,442 | ) | (33,442 | ) | ||||||||||||||||||||||||||||
Preferred stock dividends | 79,210 | (91,039 | ) | (11,829 | ) | |||||||||||||||||||||||||||
Net loss | (5,220,791 | ) | (5,220,791 | ) | ||||||||||||||||||||||||||||
Balance at March 31, 2018 | 855,833 | $ | 4,817,513 | 11,925,917 | $ | 1,192 | $ | 30,538,811 | $ | (72,032 | ) | $ | (34,743,246 | ) | $ | 542,238 |
See accompanying notes to unaudited interim consolidated financial statements.
4 |
BioHiTech Global, Inc. and Subsidiaries |
Notes to Unaudited Condensed Consolidated Financial Statements |
For the Three Months Ended March 31, 2019 and 2018 |
Note 1. Basis of Presentation and Going Concern
Nature of Operations - BioHiTech Global, Inc. (the “Company” or “BioHiTech”) through its wholly-owned and its controlled subsidiaries offers cost-effective and technologically innovative advancements integrating technological, biological and mechanical engineering solutions for the control, reduction and / or reuse of organic and municipal waste.
As of March 31, 2019 and December 31, 2018, the Company’s active wholly-owned subsidiaries were BioHiTech America, LLC, BioHiTech Europe Limited, BHT Financial, LLC and E.N.A. Renewables LLC, and its controlled subsidiary was Refuel America LLC (60%) and its wholly-owned subsidiaries Apple Valley Waste Technologies Buyer, Inc., Apple Valley Waste Technologies, LLC, New Windsor Resource Recovery LLC and Rensselaer Resource Recovery LLC and its controlled subsidiary Entsorga West Virginia LLC (78.2%).
As of March 31, 2018, the Company’s active wholly-owned subsidiaries were BioHiTech America, LLC, BioHiTech Europe Limited, BHT Financial, LLC and E.N.A. Renewables LLC, and New Windsor Resource Recovery LLC.
Basis of Presentation - The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned and controlled subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management’s opinion, however, that the accompanying condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2018, which contains the audited financial statements and notes thereto, for the years ended December 31, 2018 and 2017 included within the Company’s Form 10-K filed with the Securities and Exchange Commission (“SEC”) on April 1, 2019. The financial information as of December 31, 2018 presented hereto is derived from the audited consolidated financial statements presented in the Company’s audited consolidated financial statements for the year ended December 31, 2018. The interim results for the three months ended March 31, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019 or for any future interim periods.
Reclassifications to certain prior period amounts have been made to conform to current period presentation. These reclassifications have no effect on previously reported net loss.
Going Concern and Liquidity - For the three months March 31, 2019, the Company had a consolidated net loss of $2,261,167, incurred a consolidated loss from operations of $1,921,303 and used net cash in consolidated operating activities of $1,212,649. At March 31, 2019, consolidated total stockholders’ equity amounted to $8,777,709, consolidated stockholders’ equity attributable to parent amounted to $2,486,715 and the Company had a consolidated working capital deficit of $3,214,265. The Company does not yet have a history of financial profitability. Historically the principal source of liquidity has been the issuance of debt and equity securities. Presently, the Company does not have firm commitments to fund its present operational and strategic plans. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent on management’s further implementation of the Company’s on-going and strategic plans, which include continuing to raise funds through debt and/or equity raises. Should the Company be unable to raise adequate funds, certain aspects of the on-going and strategic plans may require modification.
The Company is presently in the process of raising additional debt and capital for general operations and for investment in several strategic initiatives, as well as commercial debt to support its leasing activities. There is no assurance that the Company will be able to raise sufficient debt or capital to sustain operations or to pursue other strategic initiatives or that such financing will be on terms that are favorable to the Company.
5 |
BioHiTech Global, Inc. and Subsidiaries |
Notes to Unaudited Condensed Consolidated Financial Statements |
For the Three Months Ended March 31, 2019 and 2018 |
Note 2. Summary of Significant Accounting Policies
Use of Estimates — The preparation of consolidated financial statements, in conformity with GAAP requires the extensive use of management’s estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates. Estimates are used when accounting for items and matters including, but not limited to, valuation of deferred tax assets, share based compensation, allowance for uncollectible accounts receivable, obsolete, slow moving and excess inventory, asset valuations, including intangibles, and useful lives and other provisions and contingencies.
Foreign Operations — Assets and liabilities denominated in foreign currencies are translated into U.S. dollars at the exchange rates existing at the respective balance sheet dates. Income and expense items are translated at the average rates during the respective periods. Translation adjustments resulting from fluctuations in exchange rates are recorded as a separate component of other comprehensive income (loss) while transaction gains and losses are recorded in net earnings (loss).
The Company pays Value Added Tax (“VAT”) or similar taxes (“input VAT”) within the normal course of its business in in the United Kingdom on merchandise and/or services it acquires. The Company also collects VAT or similar taxes on behalf of the government (“output VAT”) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, then the difference is remitted to the government, usually on a monthly basis. If the input VAT exceeds the output VAT, this creates a VAT receivable. The Company either requests a refund of this VAT receivable or applies the balance to expected future VAT payables.
Product and Services Revenue Recognition — The Company records revenue based on a five-step model in accordance with ASC 606, Revenue from Contracts with Customers, which require that we:
1. Identify the contract with a customer;
2. Identify the performance obligations in the contract;
3. Determine the transaction price of the contract;
4. Allocate the transaction price to the performance obligations in the contract;
5. Recognize revenue when the performance obligations are met or delivered.
The Company’s performance obligations are satisfied at the point in time when products are shipped to the customer, which is when the customer has title and control. Therefore, the Company’s contracts have a single performance obligation (shipment of product). The Company primarily receives fix consideration for sales of products.
Management advisory fees are recognized over the term of the agreement.
The Company records taxes collected from customers and remitted to governmental authorities on a net basis.
Lease Revenue Recognition — Rental, service and maintenance revenues relating to the Company’s rental agreements involve providing use of the Company’s digesters at customer locations, access to our software as a service and preventative maintenance over the term. The agreements generally provide for flat monthly payments that the Company believes are consistent with our costs and obligations underlying the agreements.
The Company selected the practical expedient not to separate non-lease components from lease components. The Company recognizes revenue from the rental of the digester units ratably on a monthly basis over the term of the lease, as it has determined that the rental agreements entered into in connection with its digester units qualify as operating leases, for which the Company is the operating lessor. In order to determine lease classification as operating, the Company evaluates the terms of the rental agreement to determine if the lease includes any of the following provisions which would indicate sales type lease treatment:
· | The lease transfers ownership of the underlying asset to the lessee by the end of the lease term, |
· | The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise, |
· | The Lease term is for the major part of the remaining economic life of the underlying asset. However, if the commencement date falls at or near the end of the economic life of the underlying asset, this criterion shall not be used for purposes of classifying the lease, |
· | The present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already reflected in the lease payments equals or exceeds substantially all of the fair value of the underlying asset or |
· | The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. |
6 |
BioHiTech Global, Inc. and Subsidiaries |
Notes to Unaudited Condensed Consolidated Financial Statements |
For the Three Months Ended March 31, 2019 and 2018 |
Restricted Cash — Includes Restricted cash that is restricted as to its use, as it is held by a trustee in accordance with the West Virginia Economic Development Authority bond agreement. These amounts are held by the Company’s trustee in various bank accounts segregated for specific uses related to the construction and operation of the resource recovery facility. Amounts required to meet current operations of the Company have been classified as current in the accompanying consolidated balance sheets.
HEBioT Facility under Construction — High Efficiency Biological Treatment (“HEBioT”) facility under construction include all costs incurred to bring an asset to the condition and location necessary for its intended use. Included in the capitalized costs are construction, legal, leasehold improvements, and interest. Once placed into service, these costs will be depreciated over their estimated useful lives on a straight-line basis.
MBT Facility Development Costs — The Company defers costs relating to on-going Mechanical Biological Treatment (“MBT”) facility development costs commencing upon the Company’s determination that the project will be completed. These site specific costs generally include external costs generally relating to legal, engineering and other costs relating to the acquisitions of land, permits and licenses. Upon commencement of construction, to the extent that costs relate to the facility, they are transferred to the construction in progress.
Investments in Unconsolidated Entities —The Company utilizes the equity method of accounting for investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. The Company’s proportionate share of net income or loss is included in the Company’s consolidated operations as earning or loss from unconsolidated equity basis investments. In circumstances were the Company does not have the ability to exercise significant influence or control over the operating and financial policies of the investee, the investment is carried at cost, less impairment, adjusted for subsequent changes to estimated fair value.
Deferred Financing Costs — Deferred financing costs relating to issued debt are included as a reduction to the applicable debt and amortized as interest expense over the term of the related debt instruments.
Income Taxes — Deferred income taxes are determined based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities given provisions of enacted laws. Deferred income tax provisions and benefits are based on changes to the asset or liabilities from year to year. In providing for deferred taxes, the Company considers tax regulations of the jurisdictions in which it operates, estimates the future taxable income and available tax planning strategies. If tax regulations, operating results or the ability to implement tax planning and strategies vary, adjustments to the carrying value of deferred tax assets and liabilities may be required. Valuation allowances are recorded related to deferred tax assets based on the “more than likely” criteria.
The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.
Loss per Share — The Company computes basic loss per share using the weighted-average number of shares of common stock outstanding and diluted loss per share, while the diluted loss per share also includes the effects of dilutive instruments using the “treasury method.” Dividends attributable to preferred stock, whether declared or accrued, are deducted from income attributable to common shareholders for purposes of earnings per share.
The Company’s potential dilutive instruments include convertible preferred stock, options, convertible debt and warrants. These instruments have not been considered in the calculation of diluted loss per share as they are anti-dilutive for the reported periods.
Note 3. Acquisition and Contribution Agreement
On November 28, 2018, Company entered into a definitive agreement (the “MIPS”) with Entsorga USA, Inc. (“EUSA”) whereby EUSA agreed to sell, transfer and convey to BioHiTech 2,687 membership units of Entsorga West Virginia, LLC (“EWV”) (the “Membership units”) in consideration of 714,519 shares of BioHiTech’s newly created Series E convertible preferred stock (the “Sr. E CPS). EWV is a facility under construction that is intended to utilize HEBioT technology to divert municipal solid waste from landfills and to create an EPA recognized alternative commodity fuel.
On December 14, 2018, the EUSA transaction was consummated. The 714,519 shares of Sr. E CPS were valued at $1,886,630 based on the underlying common shares which the Sr. E CPS is convertible into. The total acquisition price of $2,863,583 is comprised of the aforementioned transaction, plus $976,953 of previously held equity in EWV.
Upon consummation of the MIPS agreement BioHiTech owned a total of 4,410.4 membership units of EWV, comprised of the 2,687 units resulting from the MIPS agreement and 1,723.4 units previously acquired by BioHiTech during 2017. The 4,410.4 membership units represented 44.1% of the total membership units issued by EWV, which combined with BioHiTech’s control of EWV’s board, management and having the largest ownership block of EUSA, with the next largest block, which represents 34.1%, an entity over which BioHiTech has controlling financial interest, results in the investment being recognized in the Company’s financial statements on a consolidated basis.
7 |
BioHiTech Global, Inc. and Subsidiaries |
Notes to Unaudited Condensed Consolidated Financial Statements |
For the Three Months Ended March 31, 2019 and 2018 |
Following the consummation of the MIPS, on December 14, 2018, BioHiTech entered into a Contribution and Transaction Agreement (“CTA”) with Gold Medal Group, LLC (“GMG”) and a newly formed subsidiary Refuel America, LLC (“Refuel”) of the Company whereby GMG contributed $3,500,000 in cash and its 34.1% ownership interest in EVW (owned by GMG’s wholly owned subsidiary Apple Valley Waste Technologies, LLC) into Refuel and BioHiTech contributed it’s 44.1% interest in EWV, a technology license for a future HEBioT facility that BioHiTech carried at a value of $6,019,200 and $316,207 in capitalized costs relating to two separate HEBioT facility on-going projects. In exchange for the assets contributed, BioHiTech and GMG acquired 60% and 40%, respectively, of the membership units of Refuel, which approximate the carrying value of each of the BioHiTech and GMG assets contributed. As a result of there being a continuation in proportional ownership of the significant assets and the affiliate nature BioHiTech and GMG through a non-controlling interest of GMG being owned by BioHiTech and there being a management agreement between GMG’s largest subsidiary, Gold Medal Holdings, LLC (“GMH”) whereby BioHiTech provides executive management of GMH with control over the strategic and operational activities of GMH, the CTA transaction has been accounted for without separate acquisition accounting applied to the CTA elements.
The following presents unaudited pro forma information as if the acquisition had occurred as of January 1, 2018. The pro forma results do not include any anticipated cost synergies or other effects of the integration of the acquired company. Pro forma amounts are not necessarily indicative of the results that actually would have occurred had the acquisition been completed on the dates indicated, nor is it indicative of future operating results of the combined company.
For the Three Months Ended March 31, | ||||||||
2019 | 2018 | |||||||
Pro forma revenue | $ | 737,701 | $ | 645,726 | ||||
Pro forma net loss | (2,261,167 | ) | (5,256,782 | ) | ||||
Proforma earnings per share – basic and diluted | (0.14 | ) | (0.48 | ) |
Note 4. Investments in Unconsolidated Entities
Entsorga West Virginia LLC - Effective March 21, 2017, the Company acquired a 17.2% interest in Entsorga West Virginia LLC EWV from the original investors at their original purchase price of $60,000 for each 1% of interest in EWV ($1,034,028). From March 21, 2017 through December 14, 2018 the Company recognized the investment utilizing the equity method of accounting due to its investment and its ability to influence operations and activities of EWV. On December 14, 2018, the Company consummated an additional acquisition of 2,687 membership units that resulted in the Company gaining control of EWV. From December 14, 2018, EWV is consolidated in the accompanying condensed consolidated financial statements.
During the three months ended March 31, 2018, the Company had recognized losses through equity method accounting of $45,413.
Gold Medal Group, LLC – On January 25, 2018, the Company entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) to acquire 9.2% of the outstanding membership units (the “Units”) of GMG, which is the owner of a traditional waste management entity. Pursuant to the Purchase Agreement, the Company acquired the Units from two unrelated parties in consideration $2,250,000 paid through the issuance of 500,000 shares of the Company’s common stock.
Additionally, on January 25, 2018, the Company entered into an Advisory Services Agreement (the “ASA”). Under the ASA, the Company provides services relating to corporate development, strategic planning, operational and sales oversight and other general administrative and support services in exchange for fees annually amounting to the greater of $750,000, which was subsequently changed to $1,000,000, or 10% of GMG’s ordinary earnings before interest, taxes, depreciation and amortization. As a result of the investment and its ability to influence operations and activities of GMG, the Company initially recognized its investment utilizing the equity method of accounting on a three-month lag in reporting periods, accordingly no income or loss was recognized during the three-months ended March 31, 2018.
During 2018, the Company’s investment in GMG was diluted from 9.2% to 2.9% due to additional GMG acquisitions and investments, including the CTA with the Company. As a result of the reduction in the ownership level and accordingly, a reduction in influence, effective December 14, 2018 the Company changed its prospective accounting for GMG from the equity method to investment at cost, less impairment, adjusted for subsequent changes to estimated fair value.
Note 5. Accounts Receivable, net
Accounts receivable consists of the following:
March 31, | December 31, | |||||||
2019 | 2018 | |||||||
Accounts receivable | $ | 467,315 | $ | 513,336 | ||||
Less: allowance for doubtful accounts receivable | (125,039 | ) | (110,038 | ) | ||||
$ | 342,276 | $ | 403,298 |
Note 6. Inventory
Inventory, comprised of finished goods and parts or assemblies, consist of the following:
March 31, | December 31, | |||||||
2019 | 2018 | |||||||
Equipment | $ | 120,493 | $ | 169,540 | ||||
Parts and assemblies | 309,924 | 330,308 | ||||||
$ | 430,417 | $ | 499,848 |
8 |
BioHiTech Global, Inc. and Subsidiaries |
Notes to Unaudited Condensed Consolidated Financial Statements |
For the Three Months Ended March 31, 2019 and 2018 |
Note 7. Equipment on Operating Leases, net
Equipment on operating leases consist of the following:
March 31, | December 31, | |||||||
2019 | 2018 | |||||||
Leased equipment | $ | 2,930,065 | $ | 3,054,097 | ||||
Less: accumulated depreciation | (1,274,102 | ) | (1,305,210 | ) | ||||
$ | 1,655,963 | $ | 1,748,887 |
During the three months ended March 31, 2019 and 2018, depreciation expense included in rental, service and maintenance expense, amounted to $101,502 and $85,044, respectively.
The Company is a lessor of digester units under non-cancellable operating lease agreements expiring through December 2023. These leases generally have terms of three to five years and do not contain stated extension periods or options for the lessee to purchase the underlying assets. At the end of the leases, the lessee may enter into a new lease or return the asset, which would be available to the Company for releasing. During the three months ended March 31, 2019 and 2018, revenue under the agreements, which is included in rental, service and maintenance revenue, amounted to $341,665 and $287,628, respectively.
The minimum future estimated contractual payments to be received under these leases as of March 31, 2019 is as follows:
Year ending December 31, | ||||
2019 (remaining) | $ | 1,006,833 | ||
2020 | 1,060,290 | |||
2021 | 752,492 | |||
2022 | 467,394 | |||
2023 and thereafter | 182,959 | |||
Total minimum lease income as of March 31, 2019 | $ | 3,469,968 |
Note 8. Equipment, Fixtures and Vehicles, net
Equipment, fixtures and vehicles consist of the following:
March 31, | December 31, | |||||||
2019 | 2018 | |||||||
Computer software and hardware | $ | 112,480 | $ | 112,500 | ||||
Furniture and fixtures | 48,196 | 48,196 | ||||||
Vehicles | 50,319 | 50,319 | ||||||
210,995 | 211,015 | |||||||
Less: accumulated depreciation and amortization | (167,451 | ) | (161,987 | ) | ||||
$ | 43,544 | $ | 49,028 |
During the three months ended March 31, 2019 and 2018, depreciation expense amounted to $5,387 and $8,166, respectively.
Note 9. HEBioT Facility Under Construction
The Company is presently constructing a HEBioT facility in Martinsburg, West Virginia that is anticipated to become fully operational in 2019 and accepted its first test loads of solid municipal waste on March 29, 2019 to commence commissioning and equipment calibration. The Company capitalizes all costs incurred to bring an asset to the condition and location necessary for its intended use. Included in the capitalized costs are construction, specialized equipment, legal, leasehold improvements, and interest. Capitalized interest relates to the State of West Virginia Revenue Bonds and amounted to $618,706 for the three months ended March 31, 2019. Once placed into service in the second quarter of 2019, these componentized costs will be depreciated over their estimated useful lives on a straight-line basis.
9 |
BioHiTech Global, Inc. and Subsidiaries |
Notes to Unaudited Condensed Consolidated Financial Statements |
For the Three Months Ended March 31, 2019 and 2018 |
Note 10. MBT Facility Development and License Costs
MBT Facility Development and License Costs consist of the following:
March 31, | December 31, | |||||||
2019 | 2018 | |||||||
MBT Projects | ||||||||
New Windsor, New York: | ||||||||
Land acquisition | $ | - | $ | 66,000 | ||||
Legal | - | 46,030 | ||||||
Survey and engineering | - | 300,624 | ||||||
- | 412,654 | |||||||
Rensselaer, New York: | ||||||||
Survey and engineering | 167,153 | 153,554 | ||||||
Total MBT projects | 167,153 | 566,208 | ||||||
Technology Licenses | ||||||||
Future site | 6,019,200 | 6,019,200 | ||||||
Martinsburg, West Virginia | 1,890,000 | 1,890,000 | ||||||
Total Technology Licenses | 7,909,200 | 7,909,200 | ||||||
Total MBT Facility Development and License Costs | $ | 8,076,353 | $ | 8,475,408 |
MBT Facility Development Costs
New Windsor, New York
As of December 31, 2018, the Company was pursuing local and state permits, and other approvals required to continue development of the project. During the three months ended March 31, 2019, the Company elected to rescind an agreement for the purchase of real property with the Town of New Windsor in exchange for a return of the $66,000 paid by the Company under the rescinded contract and to relocate the project. While the Company is presently investigating several other sites for the project, as a result of abandoning the initial site, the Company has reflected an impairment expense of $346,654 relating to the site during the three months ended March 31, 2019 in selling, general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.
Rensselaer, New York
During 2018, the Company commenced initial development of a project in Rensselaer, NY. As of March 31, 2019, the Company has received local permits and has filed initial state permit applications is responding to the regulator’s comments.
HEBioT Technology Licenses
Technology License Agreement – Future Facility
On November 1, 2017, the Company entered into a Technology License Agreement (the “License Agreement”) with Entsorgafin S.p.A. (“Entsorga”) whereby the Company acquired a license for the design, development construction, installation and operation of a High Efficiency Biological Treatment (“HEBioT”) renewable waste facility with a capacity of 165,000 tons per year. The patented HEBioT technology converts mixed municipal and organic waste to a US Environmental Protection Agency recognized alternative fuel source.
The royalty payment for the license amounted to $6,019,200, which was comprised of 1,035,905 shares of the Company’s common stock, par value $0.0001 per share and cash payments in an amount up to $839,678 for Entsorga’s withholding taxes in the Unites States and Italy. The Company also entered into a Registration Rights Agreement with Entsorga whereby the Company granted Entsorga certain piggy-back and demand registration rights with respect to the Shares. This Technology License Agreement can be utilized at a future project and will be amortized once the facility is in operation.
Technology License Agreement – Martinsburg, West Virginia
In connection with the acquisition accounting applied to Entsorga West Virginia acquisition consummated on December 14, 2018, the facility License Agreement was valued at $1,890,000.
Note 11. Intangibles Assets, net
Intangible assets consist of distribution and intellectual property agreements relating to the Eco-Safe digester line, as follows:
Useful Lives (Years) |
Remaining Weighted Average Life (Years) |
Gross Carrying Amount |
Accumulated Amortization |
Net Carrying Amount |
||||||||||||
March 31, 2019 | 10 | 0.7 | $ | 902,000 | $ | (840,617 | ) | $ | 61,383 | |||||||
December 31, 2018 | 10 | 0.9 | 902,000 | (818,067 | ) | 83,933 |
10 |
BioHiTech Global, Inc. and Subsidiaries |
Notes to Unaudited Condensed Consolidated Financial Statements |
For the Three Months Ended March 31, 2019 and 2018 |
During the each of the three months ended March 31, 2019 and 2018, amortization expense, included in depreciation and amortization of operating expenses, amounted to $22,550. Future amortization amounts to $20,983 during the remained of 2019 and $20,200 in each of the years ending December 31, 2020 and 2021.
Note 12. Goodwill
As of March 31, 2019 and December 31, 2018, the Company has goodwill of $58,000 resulting from the Entsorga West Virginia, LLC acquisition on December 14, 2018. Impairment testing is performed annually at the end of the calendar year. It is not anticipated that this goodwill will be tax deductible.
Note 13. Risk Concentrations
The Company operates as a single segment on a worldwide basis through its subsidiaries, resellers and independent sales agents. Gross revenues and net non-current tangible assets on a domestic and international basis are as follows:
United States |
International | Total | ||||||||||
2019: | ||||||||||||
Revenue, for the three months ended March 31, 2019 | $ | 641,646 | $ | 96,055 | $ | 737,701 | ||||||
Non-current tangible assets, as of March 31, 2019 | 39,869,032 | 275,927 | 40,144,959 | |||||||||
2018: | ||||||||||||
Revenue, for the three months ended March 31, 2018 | $ | 572,384 | $ | 73,342 | $ | 645,726 | ||||||
Non-current tangible assets, as of December 31, 2018 | 37,151,501 | 284,444 | 37,435,945 |
Credit risk — Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and accounts receivable.
The Company minimizes credit risk associated with cash by periodically evaluating the credit quality of its primary financial institutions. At times, the Company’s cash may be uninsured or in deposit accounts that exceed the Federal Deposit Insurance Corporation (“FDIC”) in the USA and the Financial Conduct Authority (“FCA”) in the UK insurance limits. Through March 31, 2019, the Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.
Major customers — During the three months ended March 31, 2019, one customer represented at least 10% of revenues, accounting for 34.6% (Gold Medal Holdings, Inc., an unconsolidated affiliate) of revenues. During the three months ended March 31, 2018, one customer represented at least 10% of revenues, accounting for 22% (Gold Medal Holdings, Inc., an unconsolidated affiliate) of revenues.
As of March 31, 2019, no customers represented at least 10% of accounts receivable. As of December 31, 2018, one customer represented at least 10% of accounts receivable, accounting for 32.8% (Gold Medal Holdings, Inc., an unconsolidated affiliate) of accounts receivable.
Vendor concentration — During the three months ended March 31, 2019, no vendors represented at least 10% of the combined cost of revenues and change in inventory. During the three months ended March 31, 2018, two vendors represented at least 10% of costs of revenue, accounting for 37% and 16% of the combined cost of revenues and change in inventory.
As of March 31, 2019, no vendors represented at least 10% of accounts payable. As of December 31, 2018, one vendor represented at least 10% of accounts payable, accounting for 12.0% (a 1.4% shareholder) of accounts payable.
11 |
BioHiTech Global, Inc. and Subsidiaries |
Notes to Unaudited Condensed Consolidated Financial Statements |
For the Three Months Ended March 31, 2019 and 2018 |
Note 14. Line of Credit, Notes Payable, Advances, Promissory Note, Convertible Promissory Notes and Long-Term Debt
Notes, lines, advances and long-term debts are comprised of the following:
March 31, 2019 | December 31, 2018 | |||||||||||||||
Total |
Related Party |
Total |
Related Party |
|||||||||||||
Line of credit | $ | 1,470,832 | $ | - | $ | 1,469,330 | $ | - | ||||||||
Senior secured promissory note | 3,926,384 | - | 3,851,305 | - | ||||||||||||
Junior promissory note | 931,548 | 931,548 | 926,211 | 926,211 | ||||||||||||
Note payable | 100,000 | - | 100,000 | - | ||||||||||||
Advance from related party | 150,000 | 150,000 | - | - | ||||||||||||
Long term debt - current and long-term portion | 19,707 | - | 21,971 | - |
Line of Credit — On February 2, 2018, the Company’s subsidiary, BHT Financial, LLC (“BHTF”) entered into a new Credit Agreement (the “Credit Agreement”) and a Master Revolving Note (the “Note”) with Comerica that provides for a facility of up to $1,000,000, secured by the assets of BHTF. The Credit Agreement and Note were amended on November 9, 2018 to increase the facility to $1,500,000. The Note does not have any financial covenants, carries interest at the rate of 3%, plus either the Comerica prime rate or a LIBOR-based rate, (6.49% and 6.52% as of March 31, 2019 and December 31, 2018, respectively) and matures on January 1, 2020. The line of credit is secured by the assets of BHTF and is personally guaranteed by the Company’s Chief Executive Officer, Frank E. Celli and James C. Chambers, a director.
As of March 31, 2019 and December 31, 2018, the $1,500,000 balance outstanding is presented net of $34,945 in issuance costs associated with the financing, net of $5,777 and $4,275 in amortization, respectively, calculated on the effective interest method, which is included in interest expense in the accompanying consolidated statements of operations and comprehensive loss.
Michaelson Senior Secured Term Promissory Financing – On February 2, 2018, the Company and several of the Company’s wholly-owned subsidiaries entered into and consummated a Note Purchase and Security Agreement (the “Purchase Agreement”) with Michaelson Capital Special Finance Fund II, L.P. (“ MCSFF ”) to issue a senior secured term promissory note in the principal amount of $5,000,000 (the “Note”). The Note is not convertible and accrues interest at the rate of 10.25% per annum. The Note provides for certain financial covenants that were not met as of March 31, 2019 and December 31, 2018 and a waiver of such was granted by MCSFF. The Note is to be repaid in eight, equal, quarterly installments of $625,000 commencing on May 15, 2021 and ending February 2, 2023 (the “Maturity Date”). Additionally, the Note is secured by a general security interest in all of the Company’s assets as well all of the assets of the Company’s subsidiaries, excluding those of Entsorga West Virginia LLC which is subject to superior security interests relating to the Entsorga West Virginia LLC WVEDA bonds. Further, the Company’s Chief Executive Officer, guaranteed a portion of the Registrant’s obligations to MCSFF. In connection with the issuance of the Note, the Company issued MCSFF 320,000 shares of the Registrant’s common stock, par value $0.0001 per share. As of March 31, 2019 and December 31, 2018, the carrying balance of the Note is comprised of $5,000,000 face value, less $1,212,121 allocated to the common stock issued based upon the market value on the date issued, less associated amortization of $287,169 and $223,443, respectively, on the stock discount, less deferred financing costs of $211,187, less $62,523 and $51,170, respectively, of associated deferred financing cost amortization. All amortization is computed on the effective interest method and included in interest expense in the accompanying consolidated statements of operations and comprehensive loss.
Junior Promissory Note – On February 2, 2018, the Company entered into a Securities Exchange and Note Purchase Agreement (the “Exchange Agreement”) with Frank E. Celli, the Company’s Chief Executive Officer, whereby Celli exchanged $4,500,000 in a note receivable from the Company and $544,777 in advances made to the Company for $4,000,000 of the Registrant’s Series C Convertible Preferred Stock, par value $0.0001 (the “Series C Preferred Stock”) and a junior promissory note (the “Junior Note”) amounting to $1,044,477, which is carried net of discounts amounting to $135,823, less associated amortization of $22,894 and $17,557 as of March 31, 2019 and December 31, 2018, respectively. The Junior Note, which is subordinated to the senior secured note, is not convertible, accrues interest at the rate of 10.25% per annum and matures on February 2, 2024.
Note Payable — As of March 31, 2019 and December 31, 2018, the note, with interest at 10%, had a remaining balance outstanding of $100,000 and matures on January 1, 2020 and does not contain any financial covenants.
Long Term Debt — Represents two loans collateralized by vehicles with interest ranging from 1.9% to 4.99%, each with amortizing principal payment requirements through 2020 and 2022, respectively.
12 |
BioHiTech Global, Inc. and Subsidiaries |
Notes to Unaudited Condensed Consolidated Financial Statements |
For the Three Months Ended March 31, 2019 and 2018 |
Maturities of Senior Secured, Junior Promissory, Notes Payable and Long Term Debt— as of March 31, 2019, excluding discounts and deferred finance costs, which are being amortized as interest expense, are as follow:
Year Ending December 31, | Amortizing |
Non- Amortizing |
Total | |||||||||
2019 (remaining) | $ | 6,901 | $ | - | $ | 6,901 | ||||||
2020 | 4,605 | 100,000 | 104,605 | |||||||||
2021 | 4,380 | 1,875,000 | 1,879,380 | |||||||||
2022 | 3,821 | 2,500,000 | 2,503,821 | |||||||||
2023 and thereafter | - | 1,669,477 | 1,669,477 | |||||||||
Total | $ | 19,707 | $ | 6,144,477 | $ | 6,164,184 |
Note 15. Entsorga West Virginia, LLC WVEDA Solid Waste Disposal Revenue Bonds
During 2016, Entsorga West Virginia LLC (the “Borrower”) was issued $25,000,000 in Solid Waste Revenue Bonds from the West Virginia Economic Development Authority (the “WVEDA Bonds”). The WVEDA Bonds were issued in two series with one for $7,535,000 bearing interest at 6.75% per annum with a maturity date of February 1, 2026 and the second for $17,465,000 bearing interest at 7.25% per annum with a maturity of February 1, 2036. Both series were issued at par. The 2026 series was payable with interest-only payments through February 1, 2019 then annual payments of principal and semi-annual payments of interest through maturity. The 2036 series is payable with interest-only payments through February 1, 2019 then annual payments of principal and semi-annual payments of interest through maturity. Repayment of principal is by way of sinking fund.
During 2018, the 2016 Indenture Trust and Loan Agreement were amended and restated effective November 1, 2018. These amendments provided for a third series of bonds amounting to $8,000,000 bearing interest at 8.75% per annum with a maturity date of February 1, 2036, with special event triggered pre-payment requirements. This series was issued at par. The 2036 series is payable with interest-only payments through February 1, 2020 then annual payments of principal and semi-annual payments of interest through maturity. Repayment is by way of sinking fund.
The outstanding balance of the WVEDA Bonds as of March 31, 2019 and December 31, 2018 is $33,000,000, which is presented net of unamortized debt issuance costs amounting to $2,189,549 and $2,145,608, less associated amortization of $259,386 and $231,510, respectively, which includes amortization prior to the Company’s control acquisition in 2018.
The loan agreement and Indenture of trust place restrictions on the Borrower and its members regarding additional encumbrances on the property, disposition of the property, and limitations on equity distributions. The loan agreement also provides for financial covenants that will become effective two quarters following the completion of the facility or two quarters following March 31, 2019, whichever is earlier.
The future sinking fund payments by the Borrower as of March 31, 2019 are as follow:
2016 Issue 2026 Series |
2016 Issue 2036 Series |
2018 Issue 2036 Series |
Total | |||||||||||||
2019 (remaining) | $ | - | $ | - | $ | - | $ | - | ||||||||
2020 | 1,160,000 | - | 230,000 | 1,390,000 | ||||||||||||
2021 | 1,215,000 | - | 255,000 | 1,470,000 | ||||||||||||
2022 | 900,000 | - | 275,000 | 1,175,000 | ||||||||||||
2023 and thereafter | 4,260,000 | 17,465,000 | 7,240,000 | 28,965,000 | ||||||||||||
Total | $ | 7,535,000 | $ | 17,465,000 | $ | 8,000,000 | $ | 33,000,000 |
In connection with the November 1, 2018 amendment and restatement of the WVEDA Bonds, Comerica Bank issued a stand by letter of credit in the amount of $1,250,000 (the “SbyLoC”) for the benefit of the WVEDA Bond trustee that is collateralized by the Company’s cash. The SbyLoC expires on December 31, 2019 and is drawable should the Company have an unfavorable result in the complaint file by Lemartec Corporation further disclosed in Note 18.
Note 16. Equity and Equity Transactions
The Company has 50,000,000 shares of its $0.001 par common stock and 10,000,000 shares of blank check preferred stock authorized by its shareholders. As of March 31, 2019 and December 31, 2018, 14,822,956 and 14,802,956 shares of common stock have been issued; and 3,179,120 and 3,159,120 shares, respectively, of preferred stock have been designated in five series of shares, which have a total of $535,547 in accumulated, but undeclared preferential dividends as of March 31, 2019, as follows:
Authorized | Par | Stated | Shares Outstanding | ||||||||||||||
Designation | Shares | Value | Value | March 31, 2019 | December 31, 2018 | ||||||||||||
Series A Convertible Preferred Stock | 333,401 | $ | 0.0001 | $ | 5.00 | 163,312 | 163,312 | ||||||||||
Series B Convertible Preferred Stock | 1,111,200 | 0.0001 | $ | 5.00 | - | - | |||||||||||
Series C Convertible Preferred Stock | 1,000,000 | 0.0001 | $ | 10.00 | 427,500 | 427,500 | |||||||||||
Series D Convertible Preferred Stock | 20,000 | 0.0001 | $ | 100.00 | 7,500 | - | |||||||||||
Series E Convertible Preferred Stock | 714,519 | 0.0001 | $ | 2.64 | 564,519 | 564,519 |
13 |
BioHiTech Global, Inc. and Subsidiaries |
Notes to Unaudited Condensed Consolidated Financial Statements |
For the Three Months Ended March 31, 2019 and 2018 |
Under the terms of the Company’s senior lender agreements, the Company is restricted from paying dividends in cash, but is allowed to pay dividends in common stock. The Company, since its merger in 2015, has not paid any cash or stock dividends on common stock.
The consolidated financial statements include less than 100% owned and controlled subsidiaries and include equity attributable to non-controlling interests that take the form of the underlying legal structures of the less than 100% owned subsidiaries. Entsorga West Virginia LLC through its limited liability agreement and the agreements related to its WVEDA Bonds have restrictions on distributions to and loans to owners while the WVEDA Bonds are outstanding.
Series D Convertible Preferred Stock – On February 11, 2019 the Company filed a Certificate of Designation for 20,000 shares of Series D Convertible Preferred Stock that was amended on May 1, 2019 (“Sr. D CPS”). The Sr. D CPS is convertible into shares of the Company’s common stock at the price of $3.50 per share based on the Sr. D CPS’s stated value being converted. Each share of the Sr. D CPS has a stated value of $100 and has dividends at the rate of 9% payable annually in arrears in cash or at the Company’s option, in common stock based upon the then in effect conversion price. The Sr. D CPS also has an alternative dividend provision based upon the cash flow distributed to the parent from the Company’s next HEBioT facility, excluding the plant in Martinsburg, West Virginia, (the “Next Facility”) based upon the Sr. D CPS proportional investment in the facility. The Sr. D CPS also has an alternative conversion based upon a multiple the annualized EBITDA of the Next Facility converted at the higher of the conversion rate in effect or the market price of the Company’s common stock if higher.
During the three months ended March 31, 2019, the Company received subscriptions and investments totaling $750,000, which were issued 7,500 shares of Sr D CPS. In addition to the Sr. D CPS, each holder received warrants to acquire 50% of the shares that the Sr. D CPS is convertible into with an exercise price of $3.50 per share and an expiration on the fifth year anniversary.
Warrants – In connection with the issuance of convertible debt and preferred stock and in connection with services provided, the Company has the 4,308,881 warrants to acquire the Company’s common stock outstanding as of March 31, 2019, as follows:
Expiring
During the Year | Warrant Shares | Exercise
Price | ||||
2020 | 22,860 | $3.50 | ||||
2021 | 2,035,228 | $3.30 to $5.00 | ||||
2022 | 1,066,231 | $3.30 to $5.00 | ||||
2023 | 1,077,417 | $3.75 to $5.50 | ||||
2024 | 107,145 | $3.50 |
The following table summarizes the outstanding warrant activity through March 31, 2019:
Outstanding, January 1, 2019 | 4,201,736 | |||
Issued | 107,145 | |||
Exercised | - | |||
Expired | - | |||
Outstanding, March 31, 2019 | 4,308,881 |
14 |
BioHiTech Global, Inc. and Subsidiaries |
Notes to Unaudited Condensed Consolidated Financial Statements |
For the Three Months Ended March 31, 2019 and 2018 |
Note 17. Equity Incentive Plans
The Company has two equity incentive plans:
2015 Equity Incentive Plan — During 2015, the Company established the BioHiTech Global, Inc. 2015 Equity Incentive Plan, which is available to eligible employees, directors, consultants and advisors of the Company and its affiliates. The plan allows for the granting of incentive stock options, nonqualified stock options, reload options, stock appreciation rights, and restricted stock representing up to 750,000 shares. The Plan is administered by the Compensation Committee of the Board of Directors.
2017 Executive Incentive Plan — At the Annual Shareholders Meeting on June 7, 2017 the shareholders approved the 2017 Executive Incentive Plan, which is available to eligible employees, directors, consultants and advisors of the Company and its affiliates. The plan allows for the granting of incentive stock options, nonqualified stock options, reload options, stock appreciation rights, and restricted stock representing up to 1,000,000 shares. The Plan is administered by the Compensation Committee of the Board of Directors.
Compensation expense related to stock options and restricted stock was:
Three months ended March 31, | ||||||||
2019 | 2018 | |||||||
Stock options | $ | 58,388 | $ | 13,772 | ||||
Restricted stock | 239,361 | 63,868 | ||||||
Total | $ | 297,749 | $ | 77,640 |
Compensation expense related to stock options and restricted stock was reflected in the following captions within operating expenses in the condensed consolidated statements of operations and comprehensive loss:
Three months ended March 31, | ||||||||
2019 | 2018 | |||||||
Rental, service and maintenance | $ | 5,755 | $ | 3,712 | ||||
Selling, general and administrative | 291,994 | 73,928 | ||||||
Total | $ | 297,749 | $ | 77,640 |
There were no grants of options or restricted stock during the three months ended March 31, 2019.
Unvested restricted stock activity was:
Balance, January 1, 2019 | 742,741 | |||
Grants | - | |||
Vested | (14,167 | ) | ||
Balance, March 31, 2019 | 728,574 |
Note 18. Commitments and Contingencies
From time to time, the Company is involved in legal matters arising in the ordinary course of business, as of March 31, 2019 the Company was involved in the following matters.
The Company had accrued their contractual obligations but disputed payment for a consulting services agreement with Tusk Ventures LLC (“Tusk”), in which Tusk claim that it is owed $250,000 pursuant to an agreement. This matter was filed in the Supreme Court of the State of New York, New York County in April 2017. This matter was settled on April 23, 2019. In connection with the settlement, the Company issued to the plaintiff 75,000 shares of its common stock.
On February 7, 2018, Lemartec Corporation (“Lemartec”) filed a complaint against the Company in the United States District Court for the Northern District of West Virginia arising out of the construction of the Company’s resource recovery facility in Martinsburg, West Virginia alleging breach of contract and unjust enrichment. The Company has filed its answer and counterclaims for damages against Lemartec and cross claims against Lemartec’s performance bond surety, Philadelphia Indemnity Insurance Company. Trial is expected to begin in August 2019 and the Company intends to vigorously defend the complaint.
It is management’s opinion that the resolution of these known claims will not materially effect the Company’s financial position, results of operations, or cash flows. There can be no assurance, however, that unforeseen circumstances will not result in significant costs. While the Company believes that these such matters are currently not a risk material to the Company’s financial position, there can be no assurance that these or other matters arising in the ordinary course of business for which the Company is, or could be, involved in litigation, will not have a material adverse effect on its business, financial condition or results of operations.
Note 19. Leases
Effective January 1, 2019, the Company implemented Accounting Standards Codification 842, Leases. The guidance requires lessees to recognize most leases on the balance sheet but does not change the manner in which expenses are recorded in the income statement. The two permitted transition methods under the guidance are the modified retrospective transition approach, which requires application of the guidance for all comparative periods presented, and the cumulative effect adjustment approach, which requires prospective application at the adoption date.
The Company utilized the optional transition method to assess the impact of this guidance on the Company’s financial statements and related disclosures, including the increase in the assets and liabilities on our balance sheet from lessee perspective. The Company completed a comprehensive review of its leases that were impacted by the new guidance.
15 |
BioHiTech Global, Inc. and Subsidiaries |
Notes to Unaudited Condensed Consolidated Financial Statements |
For the Three Months Ended March 31, 2019 and 2018 |
As part of the adoption, the Company elected the ‘package of practical expedients,’ which permits the Company not to reassess under the new standard the Company’s prior conclusions about lease identification, lease classification and initial direct costs, therefore the Company did not restate prior comparative periods.
The Company rents its headquarters and attached warehousing space from a related party (see Note 20) and has a land lease relating to the Martinsburg, WV HEBioT facility under operating leases. The HEBioT facility land lease has an initial term of 30 years, plus four 5-year extensions. For purposes of our determination of lease liabilities, extensions were not included. As the leases do not provide an implicit rate, the Company used incremental borrowing rates in determining the present value of lease payments. For the HEBioT facility land lease a rate of 11% was utilized and a rate of 10.25% was used on the other leases. The current portion of the lease liabilities of $101,477 is included in accrued expenses and liabilities. Total rent expense under all operating leases amounted to $67,532 and $33,101 for the three months ended March 31, 2019 and 2018, respectively. Maturities of lease liabilities under these leases, which have a weighted average remaining term of 24.5 years, as of March 31, 2019 is:
Year Ending December 31, | ||||
2019 (remaining) | $ | 146,470 | ||
2020 | 150,926 | |||
2021 | 113,000 | |||
2022 | 113,000 | |||
2023 and thereafter | 3,095,500 | |||
Total lease payments | 3,618,896 | |||
Less imputed interest | (2,597,706 | ) | ||
Present value of lease liabilities | $ | 1,021,190 |
During the three months ended March 31, 2019, the Company recognized operating lease right of use assets in exchange for lease liabilities amounting to $1,045,755 and had operating cash flows for operating leases amounting to $72,765.
Note 20. Related Party Transactions
Related parties include Directors, Senior Management Officers, and shareholders, plus their immediate family, who own a 5% or greater ownership interest at the time of a transaction. The table below presents the face amount of direct related party assets and liabilities and other transactions or conditions as of or during the periods indicated.
March 31, | December 31, | |||||||||
2019 | 2018 | |||||||||
Assets: | ||||||||||
Accounts receivable | (e and f) | $ | 1,625 | $ | 168,588 | |||||
Intangible assets, net | (a) | 61,383 | 83,933 | |||||||
Liabilities: | ||||||||||
Accounts payable | (a and h) | 204,295 | 160,761 | |||||||
Accrued interest payable | - | 46,796 | ||||||||
Long term accrued interest | (c) | 1,381,914 | 1,305,251 | |||||||
Advance from related party | (b) | 150,000 | - | |||||||
Junior promissory note | (c) | 931,548 | 926,211 | |||||||
Other: | ||||||||||
Line of credit guarantee | (d) | 1,470,832 | 1,469,330 |
The table below presents direct related party expenses or transactions for the three months ended March 31, 2019 and 2018. Compensation and related costs for employees of the Company are excluded from the table below.
Three Months Ended March 31, | ||||||||||
2019 | 2018 | |||||||||
Management advisory fees | (e) | $ | 250,000 | $ | 139,383 | |||||
Project fees | (f) | - | - | |||||||
Consulting revenue | (g) | - | 29,925 | |||||||
S, G & A - Rent expense | (h) | 13,545 | 13,445 | |||||||
Cost of revenues - Rent expense | (h) | 10,992 | 10,973 | |||||||
S, G & A - Consulting expense | (a) | 18,750 | 50,000 | |||||||
Interest expense | 63,628 | 144,242 | ||||||||
Debt guarantee fees | (d) | 16,875 | 20,833 | |||||||
Cost of revenue, inventory or equipment on operating leases acquired | (a) | - | 5,707 |
16 |
BioHiTech Global, Inc. and Subsidiaries |
Notes to Unaudited Condensed Consolidated Financial Statements |
For the Three Months Ended March 31, 2019 and 2018 |
(a) | Distribution Agreement - BioHiTech has an exclusive license and distribution agreement (the “License Agreement”) with BioHiTech International, Inc., a company owned by James Koh, a BioHiTech shareholder and other unrelated parties. The License Agreement provides distribution rights to the Eco-Safe Digester through December 31, 2023 (unless extended by mutual agreement) and for annual payments to Mr. Koh in the amount of $200,000 for the term of the License Agreement and a 2.5% additional commission on all sales closed by Mr. Koh. Effective October 17, 2018, the agreement was amended to reduce the annual payments to $75,000 and to remove several international locations that the Company does not actively market. |
(b) | Advance from Related Party - The Company’s Chief Executive Officer (the “Officer”) on occasion advances the Company funds for operating and capital purposes. The advances bear interest at 13% and are unsecured and due on demand. There are no financial covenants related to this advance and there are no formal commitments to extend any further advances. |
(c) | Junior Promissory Note - On February 2, 2018, the Company entered into a Securities Exchange and Note Purchase Agreement (the “Exchange Agreement”) with Frank E. Celli, the Company’s Chief Executive Officer, whereby Celli exchanged $4,500,000 in a note receivable from the Company and $544,777 in advances made to the Company for $4,000,000 of the Registrant’s Series C Convertible Preferred Stock, par value $0.0001 (the Series C Preferred Stock”) and a junior promissory note (the “Junior Note”). The Junior Note, which is subordinated to the senior secured note, is not convertible, accrues interest at the rate of 10.25% per annum and matures on February 2, 2024. |
(d) | Line of Credit - Under the terms of the line of credit, several related parties have personally guaranteed the line and are contingently liable should the Company not meet its obligations under the line. In connection with the new line of credit entered into on February 2, 2018, the Chief Executive Officer and a Director have provided a guarantee of the line of credit in exchange for a fee representing 4.5% of the debt. |
(e) | Management Advisory Fees - The Company provides management advisory services to Gold Medal Holdings, Inc., an entity that the Company accounted for as an equity investment effective February 2018. The accounting for the investment was changed to cost method in December 2018. |
(f) | Project Fees – In addition to Management Advisory Fees, the Company also has provided to Gold Medal Holdings, Inc. non-management advisory services related to projects relating to technology and operations. |
(g) | Consulting Revenue - The Company provided environmental and project consulting to Entsorga West Virginia LLC, an entity that the Company accounted for as an equity investment from March 2017 through December 14, 2018, the date of its control acquisition. |
(h) | Facility Lease - The Company leases its corporate headquarters and warehouse space from BioHiTech Realty LLC, a company owned by two stockholders of the Company, one of whom is the Chief Executive Officer. The lease expires in 2020, with a renewal option for an additional five-year period. Minimum lease payments as of March 31, 2019 under these operating leases are: |
Year ending December 31, | ||||
2019 (remaining) | $ | 75,220 | ||
2020 | 41,926 | |||
Total | $ | 117,146 |
17 |
BioHiTech Global, Inc. and Subsidiaries |
Notes to Unaudited Condensed Consolidated Financial Statements |
For the Three Months Ended March 31, 2019 and 2018 |
Note 21. Supplemental Consolidated Statement of Cash Flows Information
Changes in non-cash operating assets and liabilities, as well as other supplemental cash flow disclosures, are as follows.
Three Months Ended March 31, | ||||||||
2019 | 2018 | |||||||
Changes in operating assets and liabilities: | ||||||||
Accounts and note receivable | $ | 48,266 | $ | (93,127 | ) | |||
Inventory | 76,930 | (350,162 | ) | |||||
Prepaid expenses and other assets | (36,508 | ) | 3,091 | |||||
Accounts payable | 3,088,732 | 134,605 | ||||||
Accrued interest payable | (399,764 | ) | 192,073 | |||||
Accrued expenses | (2,668,827 | ) | (470,738 | ) | ||||
Deferred revenue | 12,142 | 2,596 | ||||||
Customer deposits | 4,351 | (29,738 | ) | |||||
Net change in operating assets and liabilities | $ | 125,322 | $ | (611,400 | ) | |||
Supplementary cash flow information: | ||||||||
Cash paid during the period for: | ||||||||
Interest | $ | 1,082,526 | $ | 50,816 | ||||
Income taxes | - | - | ||||||
Supplementary Disclosure of Non-Cash Investing and Financing Activities: | ||||||||
Transfer of inventory to leased equipment | $ | 6,884 | $ | 164,380 | ||||
Common stock issued in settlement of accrued interest | 523,788 | |||||||
Common stock issued in acquisition of Gold Medal Group, LLC | 2,250,000 | |||||||
Conversion of notes into common stock | 3,715,374 | |||||||
In-Kind payments by investors for common and preferred stock | 216,665 | |||||||
Exchange of related party notes payable and advances for Series C preferred stock, warrants and notes payable | 4,275,000 | |||||||
Accrual of Series A preferred stock dividends | 18,372 | 91,039 | ||||||
Reconciliation of Cash and Restricted Cash: | ||||||||
Cash | $ | 1,374,564 | $ | 3,223,447 | ||||
Restricted cash (short term) | 2,137,456 | - | ||||||
Restricted cash (non-current) | 2,532,933 | - | ||||||
Total cash and restricted cash at the end of the period | $ | 6,044,953 | $ | 3,223,447 |
Note 22. Recent Accounting Standards
During the three months ended March 31, 2019, the Company adopted the following recent accounting standards:
Leases — In February 2016, the FASB issued new lease accounting guidance (ASU No. 2016-02, Leases), which has subsequently been amended by ASU No. 2018-11, Leases in July 2018. Under the new guidance, at the commencement date, lessees will be required to recognize a lease liability, which is a lessee‘s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. The new guidance is not applicable for leases with a term of 12 months or less. Lessor accounting is largely unchanged. Public business entities should apply the amendments in ASU 2016-02 for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted upon issuance. Lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. Lessees and lessors may not apply a full retrospective transition approach. ASU 2018-11 provides that under certain instances lessors may not be required to separate the components of the contracts. As a lessor of digester equipment under operating leases, the new guidance did not have a material impact on the financial statements. As a lessee under operating leases the adoption did not have a material impact on our financial statements, resulting in an increase of 2% to each of our total assets and total liabilities on our balance sheet, and had an immaterial impact to retained earnings as of the beginning of 2019. See Note 19.
18 |
BioHiTech Global, Inc. and Subsidiaries |
Notes to Unaudited Condensed Consolidated Financial Statements |
For the Three Months Ended March 31, 2019 and 2018 |
In March 2019, the FASB issued ASU 2019-01, Leases (Topic 842, Codification Improvements), which removed the requirement for an entity to disclose in the interim periods after adoption, the effect of the change on income from continuing operations, net income, any other affected financial statement line item, or per share amount. For lessors, the new leasing standard requires leases to be classified as sales-type, direct financing or operating leases. These criteria focus on the transfer of control of the underlying asset. This standard and related updates were effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2019-01 on January 2019. See Note 19 for disclosures related to this amended guidance.
Note 23. Subsequent Events
The Company evaluates subsequent events and transactions that occur after the balance sheet date up to the date that the financial statements are available to be issued. Any material events that occur between the balance sheet date and the date that the financial statements were available for issuance are disclosed as subsequent events, while the financial statements are adjusted to reflect any conditions that existed at the balance sheet date. Based upon this review, except as disclosed within the footnotes or as discussed below, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements.
Subsequent to March 31, 2019, the Company received $537,500 in additional subscriptions to its Sr. D CPS offering.
Note 24. Condensed Consolidating Financial Information
The WVEDA Solid Waste Disposal Revenue Bond obligations of Entsorga West Virginia LLC are not guaranteed by its members, including the Company, however the membership interests of Entsorga West Virginia LLC are pledged, and the debt agreements provide restrictions prohibiting distributions to the members, including equity distributions or providing loans or advances to the members.
The following presents the Company’s consolidating balance sheet as of March 31, 2019 and December 31, 2018 and its condensed consolidating statement of operations and cash flows for the three months ended March 31, 2019, for Entsorga West Virginia LLC and the Parent and other Company subsidiaries not subject to the WVEDA Solid Waste Disposal Revenue Bond restrictions and the elimination entries necessary to present the Company’s financial statements on a consolidated basis. These condensed consolidating financial information should be read in conjunction with the Company's consolidated financial statements.
19 |
BioHiTech Global, Inc. and Subsidiaries |
Notes to Unaudited Condensed Consolidated Financial Statements |
For the Three Months Ended March 31, 2019 and 2018 |
Condensed Consolidating Balance Sheet as of March 31, 2019
Parent and other Subsidiaries |
Entsorga West Virginia LLC |
Eliminations | Consolidated | |||||||||||||
Assets | ||||||||||||||||
Cash | $ | 1,372,544 | $ | 2,020 | $ | - | $ | 1,374,564 | ||||||||
Restricted cash | - | 2,137,456 | - | 2,137,456 | ||||||||||||
Other current assets | 899,278 | - | - | 899,278 | ||||||||||||
Current assets | 2,271,822 | 2,139,476 | - | 4,411,298 | ||||||||||||
Restricted cash | - | 2,532,933 | - | 2,532,933 | ||||||||||||
HEBioT facility | - | 35,899,019 | - | 35,899,019 | ||||||||||||
Other fixed assets | 1,699,507 | - | - | 1,699,507 | ||||||||||||
Operating lease right of use assets | 115,498 | 905,692 | 1,021,190 | |||||||||||||
MBT facility development and license costs | 6,186,353 | 1,890,000 | - | 8,076,353 | ||||||||||||
Intangible assets, net and investment in subsidiaries | 11,039,127 | - | (9,290,361 | ) | 1,748,766 | |||||||||||
Goodwill | - | 58,000 | - | 58,000 | ||||||||||||
Other assets | 13,500 | - | - | 13,500 | ||||||||||||
Total assets | $ | 21,325,807 | $ | 43,425,120 | $ | (9,290,361 | ) | $ | 55,460,566 | |||||||
Liabilities and stockholders’ equity | ||||||||||||||||
Line of credit | $ | 1,470,832 | $ | - | $ | - | $ | 1,470,832 | ||||||||
Other current liabilities | 2,477,624 | 3,768,777 | (91,670 | ) | 6,154,731 | |||||||||||
Current liabilities | 3,948,456 | 3,768,777 | (91,670 | ) | 7,625,563 | |||||||||||
Notes payable and other debts | 4,869,277 | - | - | 4,869,277 | ||||||||||||
Accrued interest | 1,381,914 | - | - | 1,381,914 | ||||||||||||
Non-current lease liabilities | 9,583 | 910,130 | - | 919,713 | ||||||||||||
WV EDA bonds | - | 31,069,837 | - | 31,069,837 | ||||||||||||
Total liabilities | 10,209,230 | 35,748,744 | (91,670 | ) | 45,866,304 | |||||||||||
Redeemable preferred stock | 816,553 | - | - | 816,553 | ||||||||||||
Stockholder’s equity: | ||||||||||||||||
Attributable to parent | 5,062,430 | 6,622,976 | (9,198,691 | ) | 2,486,715 | |||||||||||
Attributable to non-controlling interests | 5,237,594 | 1,053,400 | - | 6,290,994 | ||||||||||||
Stockholders’ equity | 10,300,024 | 7,676,376 | (9,198,691 | ) | 8,777,709 | |||||||||||
Total liabilities and stockholders’ equity | $ | 21,325,807 | $ | 43,425,120 | $ | (9,290,361 | ) | $ | 55,460,566 |
Condensed Consolidating Statement of Operations for the three months ended March 31, 2019
Parent and other Subsidiaries | Entsorga West Virginia LLC | Eliminations | Consolidated | |||||||||||||
Revenue | $ | 737,701 | $ | - | $ | $ | 737,701 | |||||||||
Operating expenses | ||||||||||||||||
Rental, service and maintenance expense | 304,705 | - | - | 304,705 | ||||||||||||
Selling, general and administrative | 2,057,247 | 269,115 | - | 2,326,362 | ||||||||||||
Depreciation and amortization | 27,937 | - | - | 27,937 | ||||||||||||
Total operating expenses | 2,389,889 | 269,115 | - | 2,659,004 | ||||||||||||
Loss from operations | (1,652,188 | ) | (269,115 | ) | - | (1,921,303 | ) | |||||||||
Other expenses | 311,989 | 27,875 | - | 339,864 | ||||||||||||
Net loss | $ | (1,964,177 | ) | $ | (296,990 | ) | $ | - | $ | (2,261,167 | ) |
20 |
BioHiTech Global, Inc. and Subsidiaries |
Notes to Unaudited Condensed Consolidated Financial Statements |
For the Three Months Ended March 31, 2019 and 2018 |
Condensed Consolidating Statement of Cash Flows for the three months ended March 31, 2019
Parent and other Subsidiaries | Entsorga West Virginia LLC | Eliminations | Consolidated | |||||||||||||
Cash flows from operating activities: | ||||||||||||||||
Net loss | $ | (1,964,177 | ) | $ | (296,990 | ) | $ | - | $ | (2,261,167 | ) | |||||
Adjustments to reconcile net loss to net cash used in operations | 892,106 | 31,090 | - | 923,196 | ||||||||||||
Changes in operating assets and liabilities | 63,732 | 61,590 | - | 125,322 | ||||||||||||
Net cash used in operations | (1,008,339 | ) | (204,310 | ) | - | (1,212,649 | ) | |||||||||
Cash flow from investing activities: | ||||||||||||||||
Construction in process and acquisitions of property and equipment | 188 | (2,795,012 | ) | - | (2,794,824 | ) | ||||||||||
Capital contribution to Entsorga West Virginia, LLC | (1,000,000 | ) | - | 1,000,000 | - | |||||||||||
Other investing activities | 52,400 | - | - | 52,400 | ||||||||||||
Net cash used in investing activities | (947,412 | ) | (2,795,012 | ) | 1,000,000 | (2,742,424 | ) | |||||||||
Cash flows from financing activities: | ||||||||||||||||
Issuances of debt and equity | 900,000 | 1,000,000 | (1,000,000 | ) | 900,000 | |||||||||||
Repayments of debt | (2,264 | ) | - | - | (2,264 | ) | ||||||||||
Deferred financing costs incurred | - | (43,941 | ) | - | (43,941 | ) | ||||||||||
Net cash provided by financing activities | 897,736 | 956,059 | (1,000,000 | ) | 853,795 | |||||||||||
Effect of exchange rate on cash | 19,851 | - | - | 19,851 | ||||||||||||
Cash – beginning of period (restricted and unrestricted) | 2,410,708 | 6,715,672 | - | 9,126,380 | ||||||||||||
Cash – end of period (restricted and unrestricted) | $ | 1,372,544 | $ | 4,672,409 | $ | - | $ | 6,044,953 |
Condensed Consolidating Balance Sheet as of December 31, 2018
Parent and other Subsidiaries |
Entsorga West Virginia LLC |
Eliminations | Consolidated | |||||||||||||
Assets | ||||||||||||||||
Cash | $ | 2,410,709 | $ | - | $ | - | $ | 2,410,709 | ||||||||
Restricted cash | - | 4,195,148 | - | 4,195,148 | ||||||||||||
Other current assets | 969,571 | - | - | 969,571 | ||||||||||||
Current assets | 3,380,280 | 4,195,148 | - | 7,575,428 | ||||||||||||
Restricted cash | - | 2,520,523 | - | 2,520,523 | ||||||||||||
HEBioT facility under construction | - | 33,104,007 | - | 33,104,007 | ||||||||||||
Other fixed assets | 1,797,915 | - | - | 1,797,915 | ||||||||||||
MBT facility development and license costs | 6,585,408 | 1,890,000 | - | 8,475,408 | ||||||||||||
Intangible assets, net and investment in subsidiaries | 7,626,268 | - | (5,854,952 | ) | 1,771,316 | |||||||||||
Goodwill | - | 58,000 | - | 58,000 | ||||||||||||
Other assets | 13,500 | - | - | 13,500 | ||||||||||||
Total assets | $ | 19,403,371 | $ | 41,767,678 | $ | (5,854,952 | ) | $ | 55,316,097 | |||||||
Liabilities and stockholders’ equity | ||||||||||||||||
Line of credit | $ | 1,469,330 | $ | - | $ | - | $ | 1,469,330 | ||||||||
Other current liabilities | 2,032,083 | 3,708,410 | - | 5,740,493 | ||||||||||||
Current liabilities | 3,501,413 | 3,708,410 | - | 7,209,823 | ||||||||||||
Notes payable and other debts | 4,890,322 | - | - | 4,890,322 | ||||||||||||
Accrued interest | 1,305,251 | - | - | 1,305,251 | ||||||||||||
WV EDA bonds | - | 31,085,902 | - | 31,085,902 | ||||||||||||
Total liabilities | 9,696,986 | 34,794,312 | - | 44,491,298 | ||||||||||||
Redeemable preferred stock | 816,553 | - | - | 816,553 | ||||||||||||
Stockholder’s equity | ||||||||||||||||
Attributable to parent | 3,405,551 | 5,854,952 | (5,854,952 | ) | 3,405,551 | |||||||||||
Attributable to non-controlling interests | 5,484,281 | 1,118,414 | - | 6,602,695 | ||||||||||||
Stockholders’ equity | 8,889,832 | 6,973,366 | (5,854,952 | ) | 10,008,246 | |||||||||||
Total liabilities and stockholders’ equity | $ | 19,403,371 | $ | 41,767,678 | $ | (5,854,952 | ) | $ | 55,316,097 |
21 |
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations. |
The following discussion and analysis should be read in conjunction with our unaudited interim condensed consolidated financial statements and related notes appearing elsewhere in this report on Form 10-Q. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including but not limited to those set forth under “Risk Factors” in our Form 10-K, as filed with the United States Securities and Exchange Commission, or the SEC, on April 1, 2019.
Cautionary Note Regarding Forward-Looking Statements
The information in this report contains forward-looking statements. All statements other than statements of historical fact made in this report are forward looking. In particular, the statements herein regarding industry prospects and future results of operations or financial position are forward-looking statements. These forward-looking statements can be identified by the use of words such as “believes,” “estimates,” “intends”, “plans”, “could,” “possibly,” “probably,” anticipates,” “projects,” “expects,” “may,” “will,” or “should,” “designed to,” “designed for,” or other variations or similar words or language. No assurances can be given that the future results anticipated by the forward-looking statements will be achieved. Forward-looking statements reflect management’s current expectations and are inherently uncertain. Our actual results may differ significantly from management’s expectations.
Although these forward-looking statements reflect the good faith judgment of our management, such statements can only be based upon facts and factors currently known to us. Forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond our control. As a result, our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under the caption “Risk Factors.” For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You should not unduly rely on these forward-looking statements, which speak only as of the date on which they were made. They give our expectations regarding the future but are not guarantees. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.
Overview
The Company was incorporated on March 20, 2013 under the laws of the state of Delaware as Swift Start Corp. On August 6, 2015, Swift Start Corp. entered into and consummated an Agreement of Merger and Plan of Reorganization with BioHiTech Global, Inc. and Bio Hi Tech America, LLC, after which it adopted the business plan of Bio Hi Tech, America, LLC, and changed its name to BioHiTech Global, Inc.
The Company’s vision since the merger has been to disrupt the waste management industry in North America through the development and utilization of our own practices and proprietary technologies, as well as successful practices and technologies acquired from other worldwide areas, to create the next level of a commercially viable, fully integrated, sustainable waste management company. The Company offers a suite of technologies and services that can be utilized separately or in tandem. The Company provides cost-effective technologies for on-site food waste reduction and elimination, as well as proprietary technology for the processing of solid waste from municipalities and large organizations through a mechanical and biological process that recovers certain recyclables, reduces weight and produces an E.P.A. recognized alternative fuel commodity, with significantly less materials destined for landfill.
After the merger, the Company’s initial focus was primarily on its on-going Digester business and related technologies.
During 2016 and 2017, the Company expanded from its technology-digester single product line by starting strategic initiatives in Mechanical Biological Treatment (“MBT”) facilities that rely upon High Efficiency Biological Treatment (“HEBioT”) to process waste at the municipal or enterprise level converting a significant portion of intake into an United States EPA recognized alternative commodity fuel.
During 2018, the Company made an investment in a traditional waste management company with the view of providing management services and to leveraging its operating base to deploy both our digesters and HEBioT facilities.
Also during 2018, the Company completed a step transaction that allowed the Company to control the first HEBioT facility under construction in the United States. This facility commenced commissioning during the first quarter of 2019 and will commence commercial operation in the second quarter of 2019.
The combination of on-site digester and facility based HEBioT technology results in a unique offering that provides a turn-key solution for customers seeking to achieve zero waste. The Company envisions use of its digesters for disposal of food waste at certain retail customer’s locations, with regional disposal services being directed to the Company’s HEBioT facilities. The digester cost effective technology can reduce 100% of a customer’s food waste at the source and the HEBioT process is a cost effective solution that can result in less than 20% of each customer’s waste being directed to landfills, hence resulting in a near-zero footprint.
22 |
Results of operations for the three months ended March 31, 2019
compared to the three months ended March 31, 2018
The following summarizes our operating results for the three months ended March 31, 2019 and 2018:
Three Months Ended March 31, | ||||||||||||||||
2019 | 2018 | |||||||||||||||
Revenues | $ | 737,701 | 100 | % | $ | 645,726 | 100 | % | ||||||||
Operating expenses | 2,659,004 | 360 | 1,973,215 | 306 | ||||||||||||
Loss from operations | (1,921,303 | ) | (260 | ) | (1,327,489 | ) | (206 | ) | ||||||||
Non-operating expenses | 339,864 | 46 | 3,893,302 | 603 | ||||||||||||
Net loss | (2,261,167 | ) | (306 | ) | (5,220,791 | ) | (809 | ) | ||||||||
Net loss attributable to non-controlling interests | (311,701 | ) | (42 | ) | - | - | ||||||||||
Net loss attributable to Parent | $ | (1,949,466 | ) | (264 | )% | $ | (5,220,791 | ) | (809 | )% |
Revenues increased from the three months ended March 31, 2018 to the three months ended March 31, 2019 by $91,975, or 14.2% primarily due to an increase management fees for Gold Medal Holdings, LLC, which commenced during the first quarter of 2018, and an increase in rental, services and maintenance, offset by a decrease in equipment sales resulting from the Company’s change in strategic goals of emphasizing rental units.
Operating expenses increased from the three months ended March 31, 2018 to the three months ended March 31, 2019 by $685,789, or 34.8% primarily as a result of a write-off of costs associated with a MBT site, which amounted to $346,654, $153,454 in start-up costs associated with our Martinsburg, WV HEBioT facility, an increase of $220,109 in stock based compensation due to 2018 grants, and an increase in professional fees due to the higher level of transactions, offset in part by a reduction in base compensation and related tax and fringe.
Other expenses decreased from the three months ended March 31, 2018 to the three months ended March 31, 2019 by $3,553,438, or 91.3% primarily due to interest expense relating to the valuation of warrants (a non-cash expense) decreasing by $3,293,613, combined decreases in interest expense and in equity method based investments in affiliate losses (a non-cash expense).
The following summarizes revenues for the three months ended March 31, 2019 and 2018:
Three Months Ended March 31, | ||||||||||||||||
2019 | 2018 | |||||||||||||||
Revenue: | ||||||||||||||||
Rental, service and maintenance | $ | 487,701 | 66 | % | $ | 440,493 | 68 | % | ||||||||
Equipment sales | - | - | 65,850 | 10 | ||||||||||||
Management advisory and other fees | 250,000 | 34 | 139,383 | 22 | ||||||||||||
Total revenue | $ | 737,701 | 100 | % | $ | 645,726 | 100 | % |
23 |
Revenue
Rental, service and maintenance revenue increased from the three months ended March 31, 2018 to the three months ended March 31, 2019 by $47,208, or 10.7% primarily due to the larger overall number of units deployed. As of March 31, 2019, the Company has 176 units under lease, as compared to 128 as of March 31, 2018. This increase of 48 units is primarily related to the Revolution Series of digesters that have lower customer costs.
Since 2018, the Company has been focusing its digester focus on rental units. During the three months ended March 31, 2019 there were no sales of digester units.
The management fees relate to services provided to Gold Medal Holding, LLC resulting from an Advisory Services Agreement (the “ASA”) on January 25, 2018. The increase from the three months ended March 31, 2018 to the three months ended March 31, 2019 is due to a full quarter of revenue in 2019 and an increase in the annual base fee.
Operating expenses
The following table breaks down our operating expenses by type:
Three Months Ended March 31, | ||||||||||||||||
2019 | 2018 | |||||||||||||||
Rental, service and maintenance | $ | 304,705 | 12 | % | $ | 335,962 | 17 | % | ||||||||
Equipment sales | - | - | 26,547 | 1 | ||||||||||||
Selling, general and administrative expenses | ||||||||||||||||
Personnel related: | ||||||||||||||||
Salaries and non-stock compensation | 767,434 | 29 | 832,589 | 42 | ||||||||||||
Stock based compensation | 291,994 | 11 | 73,928 | 4 | ||||||||||||
Taxes and fringe benefits | 136,080 | 5 | 150,933 | 8 | ||||||||||||
Total personnel related | 1,195,508 | 45 | 1,057,450 | 54 | ||||||||||||
Professional fees | ||||||||||||||||
Legal | 155,313 | 6 | 107,264 | 5 | ||||||||||||
Accounting | 170,272 | 6 | 142,621 | 7 | ||||||||||||
Investor relations and investment banking | 54,075 | 2 | 35,990 | 2 | ||||||||||||
Marketing | 290 | - | 987 | - | ||||||||||||
Total professional fees | 379,955 | 14 | 286,862 | 14 | ||||||||||||
Marketing | 42,457 | 2 | 102,977 | 5 | ||||||||||||
Office operations | 164,185 | 6 | 111,689 | 6 | ||||||||||||
Other | 544,257 | 20 | 21,012 | 1 | ||||||||||||
Total Selling, general and administrative | 2,326,362 | 87 | 1,579,990 | 80 | ||||||||||||
Depreciation and amortization | 27,937 | 1 | 30,716 | 2 | ||||||||||||
Total operating expenses | $ | 2,659,004 | 100 | % | $ | 1,973,215 | 100 | % |
Rental, service and maintenance expenses
Rental, service and maintenance expenses mainly consists of the cost of acquiring digester units that are leased and depreciated, warehousing, installation, maintenance, parts and shipping costs, as well as related salary and employee costs related to rental units. Rental, service and maintenance expense decreased from the three months ended March 31, 2018 to the three months ended March 31, 2019 by $31,257, or 9.3%, primarily due to improved economies of scale resulting from the increase in the number of units under rental, as well as lower maintenance costs associated with the Revolution Series of digesters. The contribution from rental, service and maintenance activities increased by $78,465, or 75.1% from $104,531 for the three months ended March 31, 2018 to $182,996 for the three months ended March 31, 2019, resulting in a contribution margin on related sales of 37.5% for the three months ended March 31, 2019, as compared to 23.7% for the three months ended March 31, 2018. This the increased scale of the activities and the result of less scheduled costs related to the Revolution Series of digesters.
Equipment sales expense
There were no equipment sales or related expenses during the three months ended March 31, 2019 due to the Company’s focus on utilizing the rental method of deployment. The Company does anticipate that equipment sales will occur in the future based upon customer requirements.
Selling, general and administrative expenses
Selling, general and administrative expenses increased from the three months ended March 31, 2018 to the three months ended March 31, 2019 by $743,593, or 46.2% primarily as a result of a write-off of costs associated with a MBT site, which amounted to $346,654, $153,454 in start-up costs associated with our Martinsburg, WV HEBioT facility, an increase of $218,066 in stock based compensation due to 2018 grants, and an increase in professional fees due to the higher level of transactions, offset in part by a reduction in base compensation and related tax and fringe.
Personnel related expenses increased from the three months ended March 31, 2018 to the three months ended March 31, 2019 by $138,058, or 13.1% in total. Stock based compensation (a non-cash expense) increased by $218,066 as a result of grants made in the second half of 2018. Base salaries and payroll decreased by $65,155, or 7.87% due to staff reductions in late 2018, offset by increases in the first quarter of 2019 by Entsorga West Virginia new staffing in connection with the startup of operations. Taxes and fringe expenses decreased by a comparable rate.
24 |
Professional fees increased from the three months ending March 31, 2018 to the three months ending March 31, 2019 by $93,093, or 32.5% in total. Legal and accounting each increased by $48,049 and $27,651, 44.8% and 19.4%, respectively, as a result of the level of strategic initiatives and costs associated with litigation.
Marketing and office operations on a combined basis decreased from the three months ended March 31, 2018 to the three months ended March 31, 2019 by $8,024, or 3.7%.
Other expenses increased from the three months ended March 31, 2018 to the three months ended March 31, 2019 by $523,245 primarily as a result of a write-off of costs associated with a MBT site, which amounted to $346,654, start-up expenses incurred at the Martinsburg, WV HEBioT facility and a $72,496 swing in the foreign currency translation for dollar denominated liabilities of our London unit moving from a negative expense of $(37,554) in 2018 to an expense of $34,942 in 2019.
Other (income) expense
Three Months Ended March 31, | ||||||||||||||||
2019 | 2018 | |||||||||||||||
Equity loss in affiliate | $ | - | - | % | $ | 45,413 | 1 | % | ||||||||
Interest expense, net | 339,864 | 100 | 554,276 | 14 | ||||||||||||
Interest expense incurred in warrant valuation and conversions | - | - | 3,293,613 | 85 | ||||||||||||
Total other expense | $ | 339,864 | 100 | % | $ | 3,893,302 | 100 | % |
Other expenses decreased from the three months ended March 31, 2018 to the three months ended March 31, 2019 by $3,553,438, or 91.3% primarily due to interest expense relating to the valuation of warrants (a non-cash expense) decreasing by $3,293,613, combined decreases in interest expense and in equity method based investments in affiliate losses (a non-cash expense).
Income tax
For the three months ended March 31, 2019 and 2018 there was no net provision for income tax due to the losses incurred and management’s evaluation of the recovery of the tax asset resulting in net operating loss carry-forward.
Liquidity and Capital Resources
For the three months March 31, 2019, the Company had a consolidated net loss of $2,261,167, incurred a consolidated loss from operations of $1,921,303 and used net cash in consolidated operating activities of $1,212,649. At March 31, 2019, consolidated total stockholders’ equity amounted to $8,777,709, consolidated stockholders’ equity attributable to parent amounted to $2,486,715 and the Company had a consolidated working capital deficit of $3,214,265. The Company does not yet have a history of financial profitability. Historically the principal source of liquidity has been the issuance of debt and equity securities. Presently, the Company does not have firm commitments to fund its present operational and strategic plans. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
The Company is presently in the process of raising additional debt and capital for general operations and for investment in several strategic initiatives, as well as commercial debt to support its leasing activities. There is no assurance that the Company will be able to raise sufficient debt or capital to sustain operations or to pursue other strategic initiatives or that such financing will be on terms that are favorable to the Company.
Cash
As of March 31, 2019 and December 31, 2018, the Company had unrestricted cash balances of $1,374,564 and $2,410,709, respectively.
Borrowings and Debt
Maturities of Senior Secured, Junior Promissory, Notes Payable and Long Term Debt — as of March 31, 2019, excluding discounts and deferred finance costs, which are being amortized as interest expense, are as follow:
Year Ending December 31, | Amortizing |
Non- Amortizing |
Total | |||||||||
2019 (remaining) | $ | 6,901 | $ | - | $ | 6,901 | ||||||
2020 | 4,605 | 100,000 | 104,605 | |||||||||
2021 | 4,380 | 1,875,000 | 1,879,380 | |||||||||
2022 | 3,821 | 2,500,000 | 2,503,821 | |||||||||
2023 and thereafter | - | 1,669,477 | 1,669,477 | |||||||||
Total | $ | 19,707 | $ | 6,144,477 | $ | 6,164,184 |
25 |
Entsorga West Virginia, LLC WVEDA Solid Waste Disposal Revenue Bonds — as of March 31, 2019, the future sinking fund payments by the Company are as follow:
2016 Issue 2026 Series |
2016 Issue 2036 Series |
2018 Issue 2036 Series |
Total | |||||||||||||
2019 (remaining) | $ | - | $ | - | $ | - | $ | - | ||||||||
2020 | 1,160,000 | - | 230,000 | 1,390,000 | ||||||||||||
2021 | 1,215,000 | - | 255,000 | 1,470,000 | ||||||||||||
2022 | 900,000 | - | 275,000 | 1,175,000 | ||||||||||||
2023 and thereafter | 4,260,000 | 17,465,000 | 7,240,000 | 28,965,000 | ||||||||||||
Total | $ | 7,535,000 | $ | 17,465,000 | $ | 8,000,000 | $ | 33,000,000 |
Cash Flows
Cash Flows from Operating Activities
We used $1,212,649 of cash in operating activities during the three months ended March 31, 2019 as compared to a use of $2,000,527 during the three months ended March 31, 2018. Our net loss during the three months ended March 31, 2019 of $2,261,167 was reduced by a loss of $346,654 resulting from the abandonment of a MBT site and $297,749 of stock based compensation charges. The net loss of 5,220,791 for the three months ended March 31, 2018 was reduced by $3,293,613 in non-cash interest expense related to the valuation of warrants and $287,512 in interest associated with the amortization of deferred financing costs and accretion of debt discounts
Cash Flows from Investing Activities
Net Cash used in investing activities for the three months ended March 31, 2019 amounted to $2,742,427 and is primarily the result of the HEBioT facility construction.
Cash Flows from Financing Activities
Cash provided by financing activities for the three months ended March 31, 2019 amounted to $853,795 and is primarily the result of our Series D convertible preferred stock offering. During the comparable 2018 period, the Company completed a series of financings that resulted in cash provided by financing activities of $4,421,885.
Off Balance Sheet Arrangements
We have not entered into any off-balance sheet arrangements during the three months ended March 31, 2019.
Item 3. | Quantitative and Qualitative Disclosures About Market Risk. |
We are a smaller reporting company as defined by 17 C.F.R. 229 (10)(f)(i) and are not required to provide information under this item.
Item 4. | Controls and Procedures. |
Evaluation of Disclosure Controls and Procedures
Our management carried out an evaluation, with the participation of our Principal Executive Officer and Principal Financial Officer, of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”).
Based upon their evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that material weaknesses existed and that the Company’s disclosure controls and procedures are not effective to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Because of our limited operations we have a small number of employees which prohibits a segregation of duties. As we grow and expand our operations, we will engage additional employees and experts as needed. However, there can be no assurance that our operations will expand.
Changes in Internal Controls Over Financial Reporting
There have not been any significant changes in our internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
26 |
Item 1. | Legal Proceedings. |
From time to time, the Company is involved in legal matters arising in the ordinary course of business, as of March 31, 2019 the Company is involved in the following matters.
The Company had accrued their contractual obligations but disputed payment for a consulting services agreement with Tusk Ventures LLC (“Tusk”), in which Tusk claim that it is owed $250,000 pursuant to an agreement. This matter was filed in the Supreme Court of the State of New York, New York County in April 2017. This matter was settled on April 23, 2019. In connection with the settlement, the Company issued to the plaintiff 75,000 shares of its common stock.
On February 7, 2018, Lemartec Corporation (“Lemartec”) filed a complaint against the Company in the United States District Court for the Northern District of West Virginia arising out of the construction of the Company’s resource recovery facility in Martinsburg, West Virginia alleging breach of contract and unjust enrichment. The Company has filed its answer and counterclaims for damages against Lemartec and cross claims against Lemartec’s performance bond surety, Philadelphia Indemnity Insurance Company. Trial is expected to begin in August 2019 and the Company intends to vigorously defend the complaint.
It is management’s opinion that the resolution of these known claims will not materially effect the Company’s financial position, results of operations, or cash flows. There can be no assurance, however, that unforeseen circumstances will not result in significant costs. While the Company believes that these such matters are currently not a risk material to the Company’s financial position, there can be no assurance that these or other matters arising in the ordinary course of business for which the Company is, or could be, involved in litigation, will not have a material adverse effect on its business, financial condition or results of operations.
Item 1A. | Risk Factors. |
We are a smaller reporting company as defined by 17 C.F.R. 229 (10)(f)(i) and are not required to provide information under this item.
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds. |
On May 10, 2019, BioHiTech Global, Inc. (the “Registrant”) entered into a series of Investor Subscription Agreements with certain accredited investors (the “Investors”), pursuant to which the Registrant agreed to sell and the Investors agreed to purchase units (the “Units”) in the aggregate offering amount of $1,287,500. Each Unit, in the minimum subscription amount of $100,000, is comprised of 1,000 Shares of the Registrant’s Series D Convertible Preferred Stock (the “Series D Preferred Shares”) and warrants (the “Warrants”) to purchase a number of shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), up to such 50% of the number of shares of Common Stock issuable upon conversion of the Series D Preferred Share at an exercise price of $3.50 per share of Common Stock.
Each share of Series D Preferred Shares have a stated value of $100.00, and is convertible into shares of Common Stock at the price of $3.50 per share based on the stated value of the Series D Preferred being converted. The Series D Preferred Shares has usual dividends at the rate of 9% payable annually in arrears in cash or, at the Company’s option, in Common Stock based upon the then in effect conversion price. The Series D Preferred Shares also have an alternative dividend provision based upon the cash flow distributed to the parent from the Company’s next HEBioT facility, excluding the Company’s plant in Martinsburg, West Virginia, (“the Next Facility”) based upon the Series D Preferred Shares proportional investment in the facility. The Series D Preferred Shares also has an alternative conversion based upon a multiple the annualized EBITDA of the Next Facility converted at the higher of the conversion rate in effect or the market price of the Company’s common stock if higher.
The Units, the Series D Preferred Shares and the Warrants were offered and sold without registration under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as provided in Rule 506(b) of Regulation D promulgated thereunder. The Units, the Series D Preferred Shares and the Warrants and the Common Stock issuable upon conversion of the Series D Preferred Shares and the Warrants have not been registered under the Securities Act or any other applicable securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act.
The Registrant paid a placement agent fee of $53,700 in cash to Network 1 Financial Securities, Inc. (the “Placement Agent”).
The Company relied on the exemptions from registration under Section 4(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. The Purchase Agreements and the Agreement contain representations to support the Company’s reasonable belief that the investors had access to information concerning the Company’s operations and financial condition, the investors acquired the securities for their own account and not with a view to the distribution thereof in the absence of an effective registration statement or an applicable exemption from registration, and that the investors are sophisticated within the meaning of Section 4(2) of the Securities Act and are “accredited investors” (as defined by Rule 501 under the Securities Act). In addition, the sale of securities did not involve a public offering; the Company made no solicitation in connection with the sale other than communications with the investors; the Company obtained representations from the investors regarding their investment intent, experience and sophistication; and the investors either received or had access to adequate information about the Company in order to make an informed investment decision.
Item 3. | Defaults Upon Senior Securities. |
None.
Item 4. | Mine Safety Disclosures. |
Not Applicable.
27 |
Item 5. | Other Information. |
On May 10, 2019, BioHiTech Global, Inc. (the “Registrant”) entered into a series of Investor Subscription Agreements with certain accredited investors (the “Investors”), pursuant to which the Registrant agreed to sell and the Investors agreed to purchase units (the “Units”) in the aggregate offering amount of $1,287,500. Each Unit, in the minimum subscription amount of $100,000, is comprised of 1,000 Shares of the Registrant’s Series D Convertible Preferred Stock (the “Series D Preferred Shares”) and warrants (the “Warrants”) to purchase a number of shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), up to such 50% of the number of shares of Common Stock issuable upon conversion of the Series D Preferred Share at an exercise price of $3.50 per share of Common Stock.
Each share of Series D Preferred Shares have a stated value of $100.00, and is convertible into shares of Common Stock at the price of $3.50 per share based on the stated value of the Series D Preferred being converted. The Series D Preferred Shares has usual dividends at the rate of 9% payable annually in arrears in cash or, at the Company’s option, in Common Stock based upon the then in effect conversion price. The Series D Preferred Shares also have an alternative dividend provision based upon the cash flow distributed to the parent from the Company’s next HEBioT facility, excluding the Company’s plant in Martinsburg, West Virginia, (“the Next Facility”) based upon the Series D Preferred Shares proportional investment in the facility. The Series D Preferred Shares also has an alternative conversion based upon a multiple the annualized EBITDA of the Next Facility converted at the higher of the conversion rate in effect or the market price of the Company’s common stock if higher.
The Units, the Series D Preferred Shares and the Warrants were offered and sold without registration under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as provided in Rule 506(b) of Regulation D promulgated thereunder. The Units, the Series D Preferred Shares and the Warrants and the Common Stock issuable upon conversion of the Series D Preferred Shares and the Warrants have not been registered under the Securities Act or any other applicable securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act.
The Registrant paid a placement agent fee of $53,700 in cash to Network 1 Financial Securities, Inc.(the “Placement Agent”).
The securities described herein were offered and sold in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D promulgated thereunder. The offering was made to “accredited investors” (as defined by Rule 501 under the Securities Act). In addition, the sale of securities did not involve a public offering; the Registrant made no solicitation in connection with the sale other than communications with the investor; the Registrant obtained representations from the investor regarding its investment intent, experience and sophistication; and the investor either received or had access to adequate information about the Registrant in order to make an informed investment decision.
Item 6. | Exhibits. |
See the exhibits listed in the accompanying “Index to Exhibits.”
28 |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BioHiTech Global, Inc. | ||
May 15, 2019 | By: | /s/ Frank E. Celli |
Name: | Frank E. Celli | |
Title: | Chief Executive Officer | |
(Principal Executive Officer) | ||
By: | /s/ Brian C. Essman | |
Name: | Brian C. Essman | |
Title: | Chief Financial Officer and Treasurer | |
(Principal Financial and Accounting Officer) |
29 |
* This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-X.
Copies of this report (including the financial statements) and any of the exhibits referred to above will be furnished at no cost to our shareholders who make a written request to our Corporate Secretary at 80 Red Schoolhouse Road, Chestnut Ridge, New York 10977
30 |